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Abstract 
 The amyloid precursor protein (APP) has been implicated in Alzheimer’s 
disease (AD) as it is cleaved by secretases to produce amyloid beta peptide (Aβ), 
which aggregates to form the extracellular amyloid plaques characteristic of AD 
pathology. In neurons, APP exists as 3 isoforms of different lengths comprising of 695 
(APP695), 751 (APP751) and 770 (APP770) amino acid residues, with APP695 being 
the major isoform present. However in AD, upregulation of the Kunitz-protease 
inhibitor (KPI) domain containing APP751 isoform was found to correlate with 
amyloid plaque density. Therefore it was believed that both Aβ and APP751 might be 
associated with the biological changes in the diseased brain.  
Interestingly, recent evidence suggests that APP might regulate glucose and 
insulin levels. Further, APP has also been associated with the development of insulin 
resistance. However, these putative functions of APP have not been studied 
extensively in neuronal cells. Since glucose hypometabolism and insulin resistance are 
associated with AD, it is likely that different isoforms of APP might modulate energy 
homeostasis differentially in the brain through regulating glucose metabolism and 
insulin signaling. Moreover, Aβ deposition has also been previously found to precede 
glucose hypometabolism, suggesting that Aβ might affect glucose metabolism. 
In this study, the effects of APP695sw and APP751sw on energy metabolism 
were assessed by generating APP expressing stable cell lines from a novel APP 
deficient neuronal cell line. APP695sw was found to increase the intracellular glucose 
content, which was accompanied by high mitochondrial activity and subsequent 
increased ROS production and caspase-3 activation. Additionally, there was also 
decreased insulin signaling in the APP695sw cells compared to APP751sw cells. 
Conversely, APP751sw cells contained lower intracellular glucose levels and 
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mitochondrial activity, thus reducing the generation of ROS and caspase-3 activation. 
Insulin signaling was also increased and restored in the APP751sw cell line. As 
reduced insulin signaling has been associated with increased tau phosphorylation, the 
higher level of insulin signaling associated with APP751sw as compared to 
APP695sw implies that the expression of APP751 in neurons might be beneficial in 
AD since it would reduce the amount of tau phosphorylation and oxidative stress. 
The effects of an increasing Aβ production on glucose metabolism were also 
examined using APPsw/PS1∆E9 mice that produce increasing Aβ with aging. A 
differential effect of Aβ on glucose metabolism was found. Specifically, a decline in 
the metabolic rate of glucose (CMRglc), marked by high brain glucose levels was 
detected at low concentrations of Aβ. When Aβ concentrations increased, a marked 
reduction in brain glucose content was observed instead, together with low brain 
insulin and glucose transporter (GLUT-4) levels. This differential effect of Aβ on 
glucose metabolism probably explains why certain imaging studies have not managed 
to find a good correlation between Aβ and CMRglc; since there is the possible 
confounding factor of impaired glucose uptake that occurs with elevated Aβ 
production.  
(467 words) 
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1. Introduction 
1.1 Alzheimer’s disease  
In recent years, Alzheimer’s disease (AD) has become a major health concern 
among the elderly population worldwide. It is the most common cause of dementia, 
flagged by early memory loss. As the disease progresses, other severe symptoms such 
as confusion, impaired judgment, difficulties in speech and the performing of simple 
daily activities manifest; often as a result of the massive neurodegeneration occurring 
in the brain (Isik 2010, Association 2010). Afflicted patients normally survive up to 4 
to 6 years after being diagnosed (Larson et al. 2004, Mehta et al. 2008).  
The vast majority of AD cases are sporadic in nature with patients developing 
symptoms at a later stage in life. The cause of sporadic AD is multifactorial and it is 
believed that genetic predisposition and environmental factors play a role in 
determining a person’s susceptibility to AD. However, inherited mutations in several 
genes such as amyloid precursor protein (APP), presenilin-1 or presenilin-2 have also 
been found to cause early onset familial AD. Yet such cases constitute only a small 
proportion of documented AD cases.     
Since the discovery of the disease in 1906 by Dr. Alois Alzheimer, the 
pathology of AD has been well characterized (Goedert & Ghetti 2007). Two distinct 
morphological hallmarks of the disease were identified, namely extracellular amyloid 
plaques and intracellular neurofibrillary tangles (NFTs). Often, sites of inflammation 
surround the plaques. Recently, advances in [18F]-fluorodeoxyglucose positron 
emission tomography imaging of glucose metabolism have established an association 
between a reduction in glucose metabolism and early stage AD (Fouquet et al. 2009). 
However, the exact cause of this impaired glucose metabolism/hypometabolism is still 
relatively unknown. 
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  Notably, the intracellular tangles contain a hyperphosphorylated form of a 
microtubule associated protein known as tau. This hyperphosphorylated form of the 
protein associates into paired helical and/or straight filaments resulting in the 
characteristic NFTs. Conversely, the extracellular plaques are composed of aggregates 
of a small peptide known as the amyloid beta peptide (Aβ) (Glenner & Wong 1984), 
which is a cleavage by-product of the amyloid precursor protein (APP) (Kang et al. 
1987, Tanzi et al. 1988).  
Aβ exists as two forms in the plaques, Aβ40 and Aβ42 that are 40 and 42 
amino acids long respectively. These two peptides differ in their length and tendency 
to aggregate, with Aβ42 being the more toxic peptide due to its readiness in 
aggregating. In particular, Aβ42 has been shown to aggregate more rapidly than Aβ40 
in aqueous solutions due to its longer hydrophobic carboxyl terminus (Burdick et al. 
1992), which promotes hydrophobic interactions between peptides (Hilbich et al. 1991, 
Snyder et al. 1994). The accumulation and aggregation of secreted peptides after the 
proteolysis of APP result in the formation of oligomers, which subsequently aggregate 
to form the extensive extracellular fibrillar plaques commonly seen in the diseased 
brain.  
Aβ oligomers appear to be more cytotoxic than fibrillar Aβ aggregates. These 
oligomers have been found to disrupt many aspects of brain function, such as synaptic 
plasticity (Shankar et al. 2007, Koffie et al. 2009), long-term potentiation (Walsh et al. 
2002) and cognitive dysfunction (Palop & Mucke 2010). Further, the deposition of the 
Aβ peptides was found to precede the development of reduced glucose metabolism in 
patients (Engler et al. 2006). This finding suggests a possible association between 
APP/Aβ and glucose metabolism, which could be a potential area for research. 
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As mentioned earlier, two major neuropathological features can be detected in 
the AD brain, namely: extracellular neuritic plaques and intracellular NFTs. These 
pathological changes can be detected in the post-mortem AD brain through the use of 
various histological staining techniques. For the former, staining dyes such as Congo 
Red or Thioflavin-S, which bind specifically to beta-sheet rich structures in the 
amyloid plaques are commonly used to visualize the pathological changes in the brain 
associated with plaque deposition. For the latter, it can be visualized through the use 
of silver impregnation methods (Braak & Braak 1991) or Thioflavin-S.  
Although amyloid plaques and NFTs are both common to AD, they display 
different deposition patterns in the brain. In particular, NFTs are usually detected in 
the allocortical region of the brain first (Arnold et al. 1991), before affecting areas 
such as the allocortex (including the hippocampus), and isocortex progressively. On 
the other hand, a study by Thal and colleagues (Thal et al. 2002) has revealed a 
different spatiotemporal pattern of deposition for amyloid plaques in the brain. 
Specifically, amyloid plaques were first detected in the isocortex, before affecting the 
allocortical and subcortical regions of the brain. Therefore for animal studies 
investigating the phenomenon of amyloid deposition in the brain, it is crucial to select 
mouse models that display a pathology similar to that in AD, in which areas such as 
the cortex and hippocampus are both affected by plaque deposition. 
Finally, although there are drugs and therapies that currently target different 
pathways or molecules involved in the pathogenesis of AD, there is no known cure for 
the disease. Existing treatments seek to delay the disease progression and to alleviate 
the symptoms of the disease. As such, there is a need to delineate the possible 
connection between early changes in the pre-AD brain (deposition and accumulation 
of Aβ) and metabolic defects that develop subsequently in AD. This might allow the 
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discovery of new pathways or molecules that can be targeted in the hopes of 
improving present treatment regimes used, which can also improve the quality of life 
of patients. 
 
1.2 Amyloid precursor protein (APP) 
1.2.1 APP gene and protein expression 
The APP gene is located on the long arm of chromosome 21. It is encoded by 
19 exons and undergoes alternative splicing at exons 7 and 8 or exon 8 alone (Ponte et 
al. 1988, Rockenstein et al. 1995) thus giving rise to three different APP mRNA 
species (Fig. 1.1). Consequently, this translates into 3 unique isoforms of the protein, 
APP695/751/770 (named based on the number of amino acids that make up the 
protein). Both APP751 and APP770 contain a domain that is homologous to the 
Kunitz-type serine protease inhibitor (KPI) domain while APP770 contains an 
additional OX2 domain (Kitaguchi et al, 1988). Conversely, APP695 contains neither 







Figure 1.1 Alternative splicing of the APP gene (adapted from Rockenstein, et al 1995). 
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Figure 1.2  Composition of the 3 different APP isoforms, APP695/751/770.  
 
The KPI domain is indicated in red while the Ox-2 domain is shaded in green.    
 
APP is a member of the APP family of proteins, which is highly conserved 
throughout different mammalian species (Walsh et al. 2007). There are two 
homologues of APP which also belong to this family, the APP like protein 1 and 2 
(APLP1 and APLP2). As these proteins share similar conserved motifs, there is some 
functional redundancy that exists between the proteins. The various functions of APP 
will be highlighted in the subsequent section of this review.     
The expression pattern of APP is well characterized. APP is present in most 
tissues including the brain. In particular, APP695 is the major isoform in neurons 
whereas the KPI positive isoforms (APP751/770) exist in a higher proportion in glial 
cells (Mattson 1997). Interestingly, the expression of various APP isoforms has been 
found to differ throughout development. A study conducted by Beyreuther and 
colleagues (Beyreuther et al. 1993) established APP695 as the major mRNA species 
in fetal brains. However they found that during aging, the relative proportion of 
different APP mRNA alters, resulting in a two-fold increase in the amount of 
APP751/770 mRNA detected in the differentiated adult brain. This suggests an overall 
increment in the amount of KPI positive APP species during development.           
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Similarly in AD, a significant increase in the amount of KPI positive, APP751 
mRNA isoforms was detected in AD brains as compared to control brains (Tanaka et 
al. 1988, Rockenstein et al. 1995, Moir et al. 1998, Preece et al. 2004). It is unclear 
whether this increase is solely due to an upregulation of the KPI isoforms in glial cells, 
an increase in the general glial cell population or whether other cell types such as 
neurons also contribute to this physiological change. As such, the KPI positive 
APP751 isoform was included in this study for a more thorough investigation of the 
subject. 
 
1.2.2 APP processing 
APP is a type I transmembrane protein with a short cytoplasmic C-terminal tail 
and a long N-terminus luminal portion. After the protein is synthesized, it is first N-
glycosylated at the endoplasmic reticulum (ER). Subsequently, it is transported to the 
Golgi apparatus, where it is further O-glycosylated and accompanied by the addition 
of tyrosine sulphate residues (De Strooper & Annaert 2000).  
A family of proteolytic enzymes termed as secretases cleave APP sequentially 
at different sites along the length of the protein. This results in the generation of two 
different species of soluble APP (sAPP) and smaller fragments of the protein. Initially, 
APP is cleaved near its C-terminus by either α- or β- secretase which causes the 
release of sAPPα (if cleavage occurs by α- secretase) or sAPPβ (if cleavage occurs by 
β- secretase). A truncated C-terminal fragment (CTF) of the protein is then left 
attached to the plasma membrane. The APP CTF is subsequently processed by another 
secretase, known as gamma secretase (γ-secretase), which results in production of 
either the amyloidogenic Aβ or the p3 fragment as shown in the diagram (Fig. 1.3). 
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Figure 1.3 Proteolytic processing of APP.  
 
In neurons, APP is processed via either the amyloidogenic pathway, resulting in the production of 
sAPPβ, Aβ and AICD or the non-amyloidogenic pathway, producing sAPPα, the p3 fragment and 
AICD.   
      
The two sAPP differ in their length, with sAPPα being the longer molecule. 
The reason for this difference lies in the cleavage site of the secretase concerned. 
Specifically, β-secretase cleaves at the N-terminus of the Aβ portion, whereas α- 
secretase cleaves between amino acids 16 and 17 of the Aβ sequence. Currently, two 
different β-secretases have been identified, namely beta-site APP cleaving enzyme 1 
(BACE1) and beta-site APP cleaving enzyme 2 (BACE2) (Yan et al. 1999). They are 
membrane-associated aspartyl proteases that cleave APP at different sites along the 
Aβ sequence. Although they belong to the same family of enzymes, they differ in their 
ability to generate Aβ.  
BACE1 was found to cleave the majority of APP at the start of the Aβ 
sequence, with a smaller portion of cleavages occurring between amino acid residues, 
 8 | P a g e  
 
Tyr-10 and Glu-11 of Aβ. Conversely, BACE2 was found to cleave more efficiently 
within the Aβ sequence at amino acid residues Phe-19 and Phe-20 (Farzan et al. 2000). 
The distinct catalytic functions of the two enzymes suggest an antagonistic role of 
these enzymes in the generation of the Aβ peptide. Interestingly, both enzymes are 
expressed in the brain with BACE1 having a slightly higher expression level (Stockley 
& O'Neill 2007). In addition, BACE has been found to function at an optimum pH of 
4.5, suggesting the enzyme is likely to cleave APP in acidic cellular compartments 
such as endosomes (Vassar et al. 1999).   
Several likely candidates for α-secretases have been isolated and identified. 
They are ADAM 9, 10 and 17 belonging to the ADAM (a disintegrin and 
metalloproteinase) family. Recent studies have identified ADAM 10 as the principal 
secretase responsible for the production of sAPPα involved in the non-amyloidogenic 
processing of APP (Kuhn et al. 2010, Jorissen et al. 2010).  Additionally, previous 
expression studies found the proteolytically active form of ADAM10 to be localized 
predominantly at the plasma membrane (Lammich et al. 1999) suggesting that non-
amyloidogenic processing of APP occurs mainly at the cell surface.      
Similar to β-secretase, γ-secretase is also an aspartyl protease. It contains 
multiple subunits that give the enzyme its catalytic properties when assembled 
together. So far, the proteins presenilin-1 (PSEN), nicastrin, anterior pharyx defective 
1 (APH-1) and presenilin enhancer-2 (PEN-2) have been verified as components of 
the protein complex (Iwatsubo 2004) that make γ-secretase functional. The γ-secretase 
enzyme cleaves APP at multiple sites within the Aβ domain resulting in the generation 
of Aβ fragments with lengths ranging from 38 to 43 amino acid residues (Selkoe & 
Wolfe 2007).  
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In addition, cleavage of APP by γ-secretase has been reported to take place in 
several intracellular compartments such as the ER, Golgi, trans-Golgi network, 
endosomes and lysosomes (Greenfield et al. 1999, Haass et al. 1992, Hartmann et al. 
1997). Further characterization studies of γ-secretase activity found the enzyme to 
function over a broad range of pH ranging from pH values of 5.5 to 7.5 (Zhang et al. 
2001).  Since γ-secretase is responsible for the final cleavage of the APP CTF to yield 
Aβ, the study of γ-secretase inhibitors as therapeutic targets for AD has been a widely 
explored area. However, since the enzyme is also known to be involved in the Notch 
signaling pathway that is important for cellular replication (Shih Ie & Wang 2007), 
there has been limited progress in the development of γ-secretase inhibitors that do not 
affect Notch processing in cells.      
                             
1.2.3 APP trafficking and localization 
APP is synthesized from the endoplasmic reticulum (ER) where it undergoes 
several trafficking routes. In neuronal cells, APP has been found to be concentrated in 
the Golgi complex (Caporaso et al. 1994). APP is also known to target to axons where 
it is inserted into the axonal membrane. For axonal sorting of APP to occur, the 
protein has to be glycosylated with an intact Aβ domain (Tienari et al. 1996). At the 
axonal surface, APP is internalized and delivered to early endosomes where it is 
further sorted and undergoes retrograde transport to the somatodendritic domain. 
Subsequently the protein is either transported to the somatic surface or the late 
endosome/lysosome compartment (Marquez-Sterling et al. 1997).  
APP can also be transported via secretory vesicles from the ER to the plasma 
membrane directly where it is internalized by receptor-mediated endocytosis (Koo & 
Squazzo 1994, Yamazaki et al. 1995). In non-neuronal cells, this process of 
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internalization occurs much more rapidly (Thinakaran & Koo 2008). An endocytosis 
motif, YENPTY located near the C-terminus of APP was found to be responsible for 
the internalization of the protein (Perez et al. 1999). APP is then delivered to 
endosomal or lysosomal compartments (Lorenzen et al. 2010) where it is further 
processed by β- and γ-secretases to generate Aβ. The Aβ generated is then secreted 
extracellularly through the secretory pathway. Moreover, in vivo studies have also 
confirmed that internalization of APP was necessary for the production of Aβ (Cirrito 
et al. 2008).  
Other than being targeted to the plasma membrane, APP is also known to 
localize to the mitochondria. A study of the structure of APP reveals a possible 
mitochondrial targeting sequence at its N-terminus. Overexpression studies of APP in 
human neuronal cell lines found an accumulation of APP in the mitochondria that 
existed in a transmembrane arrested configuration (Anandatheerthavarada et al. 2003). 
An internal acidic domain present between 220 and 290 amino acids of the APP 
protein was found to be responsible for its transmembrane arrest in the mitochondria. 
Further, in the AD brain, APP was also observed to accumulate in the mitochondrial 
import channels, where it formed complexes with the translocase of the outer 
mitochondrial membrane 40 and the translocase of the inner mitochondrial membrane 
23 (Devi et al. 2006). However, the exact conditions responsible for the targeting of 
APP to the mitochondria are still unknown.         
    
1.2.4 Functions of APP 
Transgenic mice deficient in either APP and/or APLPs have been studied to 
assess the different functional aspects of APP. Mice containing a double knockout of 
both APP and APLP2 were found to be lethal early postnatally (von Koch et al. 1997), 
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suggesting a plausible role of APP and APLP2 in development. A similar observation 
was made by Heber and colleagues (Heber et al. 2000) in a subsequent study, thus 
confirming the previous results. However, double knockout mice for APP and APLP1 
were viable; implying a certain degree of functional redundancy exists between APP 
and its two protein homologues. Following that, triple knockout mice deficient in APP 
and APLP (APLP1 and APLP2) were examined (Herms et al. 2004). Most of the mice 
died shortly after birth and presented with brain abnormalities. In particular, the 
authors reported a loss of cortical Cajal Retzius cells in the animals, which pinpoints 
the involvement of APP/APLP in areas of brain development such as neuronal cell 
survival and adhesion. Therefore it is likely that APLPs share other similar functions 
as APP. Nonetheless, more work would need to be done to verify this assumption. 
Additionally, APP has also been implicated in other aspects of neuronal 
function such as neurite outgrowth. Specifically, sAPPα that is generated through the 
non-amyloidogenic processing of APP was found to promote neurite outgrowth 
through the MAPK pathway (Gakhar-Koppole et al. 2008). Young-Pearse and 
colleagues further demonstrated that this ability of sAPPα to regulate neurite 
outgrowth was dependent on the competition between sAPPα and intracellular APP 
for binding to integrin beta1 (Young-Pearse et al. 2008), which activates axon 
elongation in the process. Further, a recent study found that both soluble forms of APP, 
sAPPα and sAPPβ could enhance axon elongation through cellular signaling in 
primary neurons (Chasseigneaux et al. 2011), suggesting alternative mechanisms in 
which neurite outgrowth is controlled by APP. The pivotal role that APP plays in 
cellular signaling processes is also clearly exemplified by these studies.  
Besides regulating neurite outgrowth, APP is also involved in ensuring the 
proper migration of neuronal precursors into the cortical plate during brain 
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development (Young-Pearse et al. 2007). The authors found that the presence of both 
the extracellular and intracellular domain of APP was essential in mediating this 
function of APP. In addition, APP is also important in modulating synapse formation 
and signal transmission. Mice that lack both APP and APLP2 were found to possess 
defective neuromuscular synapses and demonstrate aberrant neurotransmitter release 
(Wang et al. 2005). Subsequent studies on the neuromuscular synapses of APP 
deficient mice found the loss of APP to be associated with the abnormal activation of 
Ca
2+
 channels, suggesting that APP probably maintains normal synaptic transmission 
through the modulation of Ca
2+
 channels (Yang et al. 2007). Moreover, a comparison 
between the structures of the submandibular ganglion synapses of double knockout 
mice deficient in APP and APLP2 and littermate APLP2 deficient mice revealed 
marked differences in synaptic vesicle density and active zone size (Yang et al. 2005), 
further implicating a role of APP in synapse formation.  
Also, an increase in APP expression was found to affect both the pre- and 
post-synaptic compartment resulting in disrupted signal transmission across synapses 
in hippocampal neurons (Ting et al. 2007). This phenomenon was found to be caused 
mainly by Aβ since an APP mutant incapable of generating Aβ did not cause any 
disruption in signal transmission. In addition, treatment of neurons with Aβ has also 
been related to a decrease in the levels of presynaptic proteins such as dynamin 1, 
which resulted in defective vesicle endocytosis and thus synaptic dysfunction (Kelly 
& Ferreira 2007). However, it appears that Aβ also functions to maintain the normal 
physiological neuronal activity of synapses since changes in synaptic activity has been 
linked to fluctuations in Aβ levels (Cirrito et al. 2005). Moreover, the lack of APP and 
consequently Aβ has also been correlated to an increase in synapse numbers (Priller et 
al. 2006). These contradicting results suggest that Aβ might be detrimental to synaptic 
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activity at exceedingly high levels while basal levels of Aβ are required for the normal 
functioning of synapses.  
Other than exerting effects on brain development and neuronal function, APP 
and APLP2 has also been reported to regulate cerebral thrombosis in vivo (Xu et al. 
2009). The authors also found that purified KPI domains could inhibit clotting of 
plasma in vitro. The results published were in line with previous findings from the 
same group that correlated KPI-containing APP isoforms with the regulation of 
cerebral thrombosis (Xu et al. 2005, Xu et al. 2007). Since APLP2 also contains a KPI 
domain, it is likely that the presence of this domain results in the ability of both APP 
and APLP2 to limit cerebral thrombosis. Additionally in other cells such as fibroblasts, 
the trans-interaction of APP family proteins has also been found to promote cell 
adhesion (Soba et al. 2005).               
Interestingly, recent studies have uncovered novel putative functions of APP 
that were previously unknown. In particular, Needham and colleagues analysed the 
plasma of double knockout mice deficient in APP and APLP2 and found that these 
mice displayed hyperinsulinemia and low glucose levels (Needham et al. 2008). This 
finding suggests that APP might have an added function in modulating glucose levels 
and energy homeostasis. Another study conducted on adipocytes reported a 
correlation between an increase in APP expression and the development of insulin 
resistance that is common in obesity (Lee et al. 2008), implying that APP might 
potentially regulate insulin signaling. Taken together, these results suggest that APP is 
important in many diverse cellular functions and might also play a role in energy 
homeostasis through controlling glucose metabolism and insulin signaling in cells. 
However, more studies would need to be performed before this hypothesis can be 
verified. 
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1.2.5 Mutations in the APP gene 
Over the years, various missense mutations in the APP gene have been 
identified. In particular, a search in the Alzheimer’s disease and frontotemporal 
mutation database confirmed a total of approximately 39 such mutations, most of 
which are pathogenic. In general, these mutations usually cause a single amino acid 
substitution, which are clustered near regions where α-, β- or γ-secretase cleaves the 
protein.  
The first APP mutation was identified from linkage studies of a rare disorder 
known as hereditary cerebral hemorrhage with amyloidosis of the Dutch type 
(HCHWA-D) (Van Broeckhoven et al. 1990). As this disorder was previously 
associated with the deposition of amyloid in the brain (van Duinen et al. 1987), the 
underlying implication is that mutations in APP might be associated with amyloid 
deposition, which prompted further studies of the APP gene.  
Subsequently, other mutations in the APP gene were identified, most of which 
were associated with an increased production of Aβ. As mentioned, a significant 
number of these mutations are located near the cleavage sites of the secretases on the 
protein. Further studies revealed an association between APP gene mutations and the 
enzymatic activity of secretases, with some mutations found to increase the β- or γ- 
secretase activity, and some to decrease the α-secretase activity thus resulting in an 
overall increase in Aβ production. 
For example, the Swedish mutation (KM670/671/NL, the only mutation 
located near the site of β-secretase cleavage) (Mullan et al. 1992) that is characterized 
by a double amino acid substitution at amino acid residues 670 and 671 increases the 
production of both species of Aβ, Aβ40 and Aβ42 through increasing the activity of β-
secretase. (Perez et al. 1996) 
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Conversely, APP containing other mutations such as the Austrian T714I, 
German V715A, Florida I716V, Indiana V717L and London V717I mutations (that 
are located near the site of γ- secretase cleavage) were found to increase the ratio of 
Aβ42 to Aβ40 in the culture medium of cells that overexpressed mutant APP (De 
Jonghe et al. 2001). These mutations are believed to alter the preferred cleavage site 
of γ- secretase on APP, thus resulting in an increased production of Aβ42 or a 
reduction in Aβ40 production, which increases the Aβ42 to Aβ40 ratio. Lastly, other 
mutations such as the Arctic mutation (APP E693G) (Nilsberth et al. 2001) that are 
located near the cleavage site of α-secretase have been found to promote aggregation 
of the Aβ peptide, resulting in increased protofibril formation. 
Since these mutations alter different aspects of Aβ production, they are 
commonly used in APP overexpression studies in cellular and animal models. 
Therefore, introducing a mutation (such as the Swedish mutation) in the APP isoforms 
selected for this study would allow the simulation of an AD-like condition, which 
would yield more meaningful results. 
1.3 The APPsw/PS1∆E9 mouse model of AD 
Transgenic mouse models have provided scientists with a means of tracking 
and studying the molecular mechanisms of disease in vivo. To simulate the 
physiological conditions in AD associated with an increasing Aβ deposition rate in the 
brain, the APPsw/PS1∆E9 mouse model was used. This strain of mice was engineered 
to express two different transgenes in the brain, namely: 1) a mouse APP gene that 
was humanized within the Aβ region and that harbored the Swedish mutation at amino 
acids 595 and 596; and 2) the human presenilin 1 (PS1) gene containing the exon 9 
deletion (∆E9) mutation. Both gene mutations have been associated with an increase 
in the amount of Aβ production in cases of familial AD (Steiner et al. 1999).       
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This transgenic mouse strain was created in 2001 by Jankowsky and 
colleagues (Jankowsky et al. 2001) using a coinjection strategy. Both transgenes were 
cloned individually into the MoPrP.Xho vector at the Xho I site between PrP exons 2 
and 3. The MoPrP.Xho vector contains the mouse prion protein (PrP) promoter, which 
ensures that transgenes would be expressed mainly in the brain. A previous study of 
the MoPrP.Xho vector also confirmed predominant expression of genes in the brain 
and trace amounts of it in the hearts of transgenic mice (Borchelt et al. 1996) when the 
vector was used to create the transgenic animals.  
To create the APPsw/PS1∆E9 mouse, plasmids containing the transgenes were 
mixed together before they were coinjected into the pronuclei of single cell embryos 
derived from F2 hybrids of C57BL/6J mice and C3H/HeJ mice. The embryos were 
then surgically transferred to surrogate mothers and allowed to develop. Transgenic 
pups born were then genotyped to assess the expression levels of the respective 
transgenes. 
Subsequent studies performed on the established APPsw/PS1∆E9 transgenic 
mouse line revealed that these animals typically developed plaques at around 6 
months of age. When the mice reached 9 months of age, most animals displayed a 
significant plaque burden. The amyloid plaque pathology was most pronounced in the 
cortex and hippocampus (Jankowsky et al. 2004). Therefore, this makes the 
APPsw/PS1∆E9 mouse model an ideal candidate for studying the effects of an 
accelerated deposition of Aβ in vivo in the brain. 
 
1.4 Diabetes and insulin signaling in AD 
Analogous to AD, diabetes has also risen through the ranks to become a chief 
health issue among the elderly.  
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A handful of population-based cohort studies have revealed type 2 diabetes 
mellitus (T2DM) as a possible risk factor for sporadic AD (Haan 2006). Type 2 
diabetes is characterized by high blood glucose levels and the development of insulin 
resistance. Generally, it was found that the risk of developing sporadic AD for an 
individual with T2DM was at least two fold higher than that of normal healthy 
individuals. This association between T2DM and AD was also supported by previous 
studies conducted such as the Rotterdam study (Ott et al. 1998) and the Honolulu-Asia 
study in 2002 (Peila et al. 2002). 
A recent study published by Takeda et al. in which diabetic AD mice were 
created from a cross between an AD and T2DM mouse model were studied (Takeda et 
al. 2010) showed that diabetes aggravates the cognitive dysfunction associated with 
AD.  Interestingly, this cognitive defect was not associated with an elevated Aβ 
content but rather a decrease in insulin levels and signaling. This reduction in insulin 
signaling was marked by a decrease in the phosphorylation of Akt, a key molecular 
player involved in the insulin signaling cascade. Therefore although T2DM does not 
appear to be responsible for the extensive Aβ deposition in AD, this recent study 
clearly identified T2DM as a contributing factor to the loss of cognitive function in the 
pathogenesis of AD.  
However, other studies conducted on animal models of obesity and T2DM 
found that T2DM alone was insufficient to cause AD pathology despite animals 
exhibiting brain atrophy and peripheral insulin resistance among other symptoms 
(Moroz et al. 2008). Despite the absence of a direct causative effect of diabetes on AD, 
current data available suggests that the prognosis of AD worsens for patients who are 
also diagnosed with diabetes.         
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Unexpectedly, the brains of AD patients with no diabetes have also been found 
to exist in an insulin resistant state with impaired activation of insulin signaling, 
reminiscent of the physiological changes characteristic of diabetes (Correia et al. 
2011). In particular, AD has recently been classified as a form of diabetes with the 
term “Type 3 diabetes” being coined for it since it displays characteristics of both type 
1- and type 2- diabetes (Kroner 2009). Specifically in “Type 3 diabetes”, an overall 
deficiency in peripheral and brain insulin is detected that is coupled with chronic 
insulin resistance, which is typical of type 2 diabetes. Not surprisingly, postmortem 
analysis of brains of patients with late-stage AD revealed a decrease in the mRNA 
levels of molecular players involved in insulin signaling, such as insulin, insulin-like 
growth factors (IGF) and their respective receptors – a clear indication of the 
development of insulin resistance in the AD brain (Moloney et al. 2010, Steen et al. 
2005, Neumann et al. 2008).    
A direct link between brain insulin signaling dysfunction and AD was further 
confirmed when streptozotocin, a diabetes inducing drug was injected into the brains 
of rats. Although the rats did not develop T2DM, an overall decrease in key insulin 
signaling components were detected (de la Monte & Wands 2008, Lester-Coll et al. 
2006). This translated into neurological defects commonly seen in AD such as 
increased levels of APP and Aβ, phosphorylated tau. In addition, learning deficits 
associated with neurodegeneration were also documented in these mice, which further 
strengthen the association between reductions in insulin signaling and AD. 
Clinical studies also seem to support the strong correlation between AD and 
insulin signaling. Specifically, early-stage AD patients had a better prognosis that was 
accompanied by improvements in cognition when they were administered with 
intranasal insulin (Craft et al. 1996). However, the pathways triggered by insulin in 
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the brain to bring about such an effect are unknown. Since insulin regulates the level 
of glucose in our body and the association between insulin signaling and AD has been 
established, it becomes pertinent for the insulin signaling pathway to be assessed 
together with alterations in glucose metabolism in this study relating APP and energy 
homeostasis. 
 
1.4.1 Insulin signaling in the brain 
Insulin is a hormone that is critical for the maintenance of energy homeostasis 
(Gerozissis 2004). Previously the source of insulin in the brain was thought to be of 
pancreatic origin and synthesized exclusively by beta cells present in the pancreas. It 
was generally believed that insulin produced from the pancreas is released into the 
blood stream where it can be transported into the brain across the blood brain barrier 
(Margolis & Altszuler 1967) through the action of unidentified insulin transporters 
(Banks 2004). Interestingly, further studies have revealed that the brain itself is also 
capable of synthesizing insulin (Clarke et al. 1986, Devaskar et al. 1994), suggesting 
that insulin in the brain potentially comes from two sources, the pancreas and the 
brain itself.  
In this section, emphasis will be placed on the molecular mechanisms of 
insulin in the brain and the players involved in brain insulin signaling. In particular, 
the effect of insulin on the insulin receptor substrate/phosphatidylinositol-3-
kinase/protein kinase B (IRS/PI3K/Akt) pathway will be highlighted (Fig. 1.4).  
Insulin signaling is initiated by the binding of insulin to insulin receptors, 
which are widely expressed in the brain (Havrankova et al. 1978). The insulin 
receptor (IR) then undergoes autophosphorylation at tyrosine residues once it is bound 
by insulin and is activated, thus initiating subsequent downstream signaling events 
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(Niswender et al. 2003a, Niswender et al. 2003b). Autophosphorylation of the IR 
serves as a signal to recruit insulin receptor substrate (IRS) proteins, IRS-1 and IRS-2, 
which act as docking proteins to recruit downstream signaling molecules. Both IRS 
proteins have been found to bind to phosphorylated motifs on the insulin receptor via 
their pleckstrin homology domain and phosphotyrosine binding domain (White 1998).   
Subsequently, the IRS proteins will then bind to src homology 2 domain 
containing signaling molecules such as the p85 regulatory subunit of PI3K directly. 
The p85 subunit in turn activates the p110 catalytic subunit of PI3K. Once activated, 
PI3K will phosphorylate PI 4, 5-biphosphate (PIP2), generating PI 3, 4,5-
trisphoshpate (PIP3), an important signaling intermediate that recruits and activates 
various downstream proteins such as phosphoinositide 3-dependent kinase 1 (PDK1) 
and Akt. This brings both PDK1 and Akt at close proximity with each other at the 
plasma membrane, thus allowing the phosphorylation and activation of Akt by PDK1 
(Vanhaesebroeck & Alessi 2000). Once activated, Akt can then proceed to regulate a 
diverse array of cellular processes.  
 
1.4.1.1 IRS expression in the brain 
The expression of both IRS-1 and IRS-2 in the brain is well characterized. 
IRS-1 has been shown to be co-expressed with insulin receptors in discrete 
populations of neurons in brain regions like the hippocampus and the olfactory bulb 
(Baskin et al. 1994). A similar study done on rat brain found that IRS-1 was localized 
in neurons from several brain regions and the spinal cord (Folli et al. 1994). 
Additionally, IRS-2 is also expressed in various brain regions such as the cerebrum, 
the cerebellum, and the hypothalamus (Taguchi et al. 2007). The presence of both IRS 
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proteins in the brain implies that insulin signaling pathways are active in neuronal 
cells and probably play an important role in brain functioning.  
 
1.4.1.2 Akt activation and signaling pathways 
As mentioned previously, Akt is activated by PDK1, which phosphorylates the 
protein at its Thr308 amino acid residue (Vanhaesebroeck & Alessi 2000). Another 
enzyme, PDK2 that has recently been identified as mammalian target of rapamycin 
(mTOR) phosphorylates Akt within its carboxy terminus at the Ser473 amino acid 
residue (Sarbassov et al. 2005). The dual phosphorylation of Akt at both Thr308 and 
Ser473 is essential for the complete activation of this kinase. 
Akt serves as an important checkpoint for the activation of various pathways. 
In this thesis, the effect of Akt activation on GLUT-4 translocation and glycogen 
synthase kinase 3β (GSK-3β) will be examined. GLUT-4 is a glucose transporter 
molecule that was found to be expressed in various brain regions, with the highest 
concentration of transporter molecules present in the cerebellum (Vannucci et al. 
1998). Subsequent studies found the activation of Akt to induce the translocation of 
GLUT-4 vesicles to the cell surface (Ducluzeau et al. 2002), which affected the 
uptake of glucose. This finding links insulin signaling to glucose uptake, highlighting 
the relative importance of insulin signaling in brain energy metabolism.  
In addition, an increase in the activity of GSK-3β, which occurs when the 
phosphorylation of GSK-3β by Akt decreases, has also been associated with 
promoting the hyperphosphorylation of tau (Rankin et al. 2007), which would 
contribute to the pathogenesis of AD by showing an increased tendency to aggregate 
into neurofibrillary tangles; thus making GSK-3β an interesting candidate to examine 
in insulin signaling as well. 
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Figure 1.4 Schematics of an overview of the insulin signaling mechanism. 
 
 
1.5 Impaired glucose metabolism in AD 
Glucose is an essential source of energy for the brain (Magistretti & Pellerin 
1996). Therefore, the metabolism of glucose is also an important process in the brain. 
Glucose diffuses from the blood into the brain via the blood brain barrier, where it is 
metabolized to produce ATP to meet the energy demands of the brain. Generally, 
glucose undergoes glycolysis to generate pyruvate, which enters the tricarboxylic 
(TCA) cycle before undergoing mitochondrial oxidative phosphorylation to produce 
36 ATP molecules per molecule of glucose.   
As mentioned previously, defects in glucose metabolism have been detected in 
various imaging studies of AD brains, with an overall decline of glucose uptake being 
reported (Swerdlow 2007). Previously, it was believed that the pronounced drop in 
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glucose metabolism was associated with the appearance of Aβ deposits in the early 
AD brain as Aβ deposition seemed to precede glucose hypometabolism (Jack et al. 
2010). Recent imaging initiatives however suggested the absence of any link between 
Aβ deposition and glucose hypometabolism (Rabinovici et al. 2010). Therefore, more 
studies would need to be performed before any association can be made between Aβ 
and glucose hypometabolism. 
Despite that, a clear correlation was found between the age of onset of AD and 
glucose hypometabolism (Rabinovici et al. 2010). Moreover, several imaging studies 
have also found a correlation between decreases in glucose metabolism and brain 
atrophy in AD patients (Yamaguchi et al. 1997). In particular, hypometabolism was 
found to occur before changes in brain atrophy in pre-symptomatic early-onset 
familial AD patients (Mosconi et al. 2006). These numerous findings attest to the 
suitability of using decreases in the cerebral metabolic rate for glucose (CMRglc) as a 
biomarker for AD.         
Biochemical analysis of AD brain tissues has also shed some light on the 
association between impaired energy metabolism and AD. In particular, a marked 
increase in pyruvate and lactate levels was measured in the cerebrospinal fluid of 
canines afflicted with senile dementia (Pugliese et al. 2005) and patients diagnosed 
with AD and vascular dementia (Parnetti et al. 2000). This suggests a possible shift 
from oxidative phosphorylation in the AD brain to aerobic glycolysis, in which 
glucose is converted to pyruvate without entering the TCA cycle, which provides a 
ready supply of ATP to meet the energy demands of the brain.     
Apart from changes in the levels of metabolites, alterations in the expression 
levels of genes and proteins involved in glucose metabolism have also been revealed 
through gene expression analysis and global proteome profiling of MCI and AD post-
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mortem brains. A general decline in the gene expression profile of metabolic enzymes 
was found in posterior cingulate neurons and brain regions affected in AD (Liang et al. 
2008).   
Subsequently, Sultana and colleagues ((Sultana et al. 2009) performed a 
proteome profiling of oxidatively modified proteins in MCI and AD cases. The results 
of their study yielded a handful of proteins such as lactate dehydrogenase, 
glyceraldehyde-3-phosphate dehydrogenase, voltage dependent anion channel, and 
ATP synthase that were found to be oxidatively modified in the AD brain. 
Collectively these proteins are key players involved at various stages of glycolysis and 
oxidative phosphorylation. Oxidative modification of these proteins would render 
them dysfunctional, which might translate to a phenotype of an impaired energy 
metabolism. Further, the expression of other crucial proteins involved in glucose 
metabolism such as complexes III and IV of the mitochondria and NADH ubiquinone 
oxidoreductase was also found to be reduced in AD (Kim et al. 2001, Kim et al. 2000). 
These alterations in protein expression level are likely to contribute to decreases in 
energy production in the brain.    
The activity level of citric acid cycle enzymes such as pyruvate dehydrogenase, 
isocitrate dehydrogenase and α-ketoglutarate dehydrogenase was also found to be 
drastically reduced in AD (Bubber et al. 2005). An overall decline in the electron 
transport chain activity was also documented in AD brains (Parker et al. 1994), along 
with reductions in the mitochondrial COX IV complex activity in the mitochondria 
and brains of AD patients (Maurer et al. 2000, Bosetti et al. 2002). These changes 
potentially contribute to mitochondrial dysfunction and the resulting commonly 
reported decrease in energy metabolism in AD. 
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Taken together, the findings listed above clearly demonstrate an association 
between AD and glucose metabolism, in many facets of the pathways involving the 
breakdown of glucose to yield energy in the brain. As such, other than examining 
overall changes in glucose concentration in our study, it would also be crucial to 
investigate alterations in i) the expression and activity level of various enzymes 
involved in glucose metabolism or ii) the levels of intermediate metabolites, for a 
deeper understanding of how APP affects energy homeostasis. 
                                 
1.6 Aims of this study 
This study aims to explore the novel and putative function of APP in the 
modulation of energy homeostasis in the context of glucose metabolism. The basis for 
this study stems from previous findings that report the involvement of APP with 1) the 
regulation of glucose and insulin levels (Needham et al. 2008) and 2) the development 
of insulin resistance (Lee et al. 2008). Particular emphasis is placed on the effect of 
APP on energy homeostasis in neuronal cells and the brain. 
Two different aspects of APP and their effects on energy homeostasis will be 
covered. Firstly, the role of APP isoforms in glucose metabolism and insulin signaling 
will be examined using neuronal cell lines deficient in APP that have been transfected 
with 2 different human APP isoforms. The KPI-containing APP isoform, APP751 was 
included in this study as APP751 is commonly known to be upregulated in AD in 
contrast to APP695. Further, since AD is characteristically associated with impaired 
energy metabolism and the development of brain insulin resistance, it was of interest 
to determine if and how different APP isoforms might contribute to these 
physiological changes. 
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In particular, Swedish mutant constructs of APP were used in the cellular 
studies as the Swedish mutation in APP promotes the formation of Aβ by causing an 
increase in the β-secretase activity (Haass et al. 1995). Therefore, using Swedish APP 
mutant constructs over wildtype constructs will allow me to mimic the conditions in 
AD in which there is an increased β-secretase activity (Li et al. 2004) that is 
accompanied by an increased production of Aβ, and an increase in the amount of KPI-
positive APP isoforms. 
Secondly, the effect of an increasing Aβ concentration on energy homeostasis 
in vivo will also be examined. Since there are current conflicting views on the 
association (or lack thereof) between Aβ and glucose metabolism, it would be 
meaningful to address this issue with in vivo models. Thus by using the 
APPsw/PS1∆E9 transgenic mouse model that produces increasing amounts of Aβ 
deposition with aging, the effects of the proteolytic cleavage product of APP, Aβ on 
energy homeostasis in the brain were determined.  
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2. Materials and methods 
2.1 Antibodies 
The following primary antibodies were used for immunoblotting analysis. 
Rabbit polyclonal antibody reacting to the C-terminal of β-actin (Sigma, St Louis, MO, 
USA); monoclonal antibodies, anti-22C11 (Millipore, Massachusetts, USA) and anti-
6E10 (Covance, New Jersey, USA) binding to amino acids 66 to 81 of human APP 
and amino acids 1 to 17 of the human Aβ region respectively. Polyclonal antibodies 
binding to insulin receptor β subunit (IR) and insulin growth-factor 1 receptor (IGF-
1R) were also used (Cell Signaling Technology, Danvers, USA).  
Further, polyclonal antibodies from the following antibody sampler kits (Cell 
Signaling Technology, Danvers, USA) were used. These include: IRS Antibody 
Sampler kit, Phospho-Akt Pathway Antibody Sampler kit and GSK3 Antibody 
Sampler kit. The following antibodies were used from these kits: anti-IRS-1/2, anti-
PI3K, anti-Akt, anti-phosphoAkt (Thr308 and Ser473), anti-phosphoPDK1, anti-
GSK3α/β, anti-phosphoGSK3α (Ser21) and anti-phosphoGSK3β (Ser9). 
Additionally, secondary antibodies used include: HRP-conjugated goat anti-
mouse IgG (Millipore, Massachusetts, USA) and HRP-conjugated goat anti-rabbit IgG 
(Millipore, Massachusetts, USA). Primary antibodies were used at a dilution factor of 
1:1000 while secondary antibodies were used at a dilution factor of 1:5000 for 
immunoblotting analysis.      
    
2.2 Animal models 
The experimental protocols involving the maintenance and euthanasia of 
laboratory mice were in accordance with guidelines approved by the Institutional 
Animal Care and Use Committees at the National University of Singapore. Mice used 
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in this study were hemizygous mutant APPsw/PS1∆E9 mice (Jankowsky et al. 2001) 
from Jackson Immuno-Research, West Grove, PA, USA, while their wildtype 
littermates were used as controls. Female transgenic mice were used at 4 ages: 3 
months, 6 months, 12 months and 15 months respectively. Four brains (n = 4) from 
each time point in the animal groups were used in all analysis. 
 
2.3 Molecular cloning 
2.3.1 Gateway® cloning 
The cDNA of wildtype human APP695 and APP751 were kindly gifted to us 
by Dr. Man-Sun Sy. Subsequently, site-directed mutagenesis was performed to create 
Swedish mutant constructs of the APP cDNA sequences, APP695sw and APP751sw. 
Briefly, double nucleotide mutations (AA  CC) were made at nucleotides at position 
1785 and 1786 of the APP695 cDNA to generate APP695sw. Similarly, these 
mutations were repeated for nucleotides at position 1953 and 1954 of the APP751 
cDNA to generate APP751sw. The cDNA sequences of APP695sw and APP751sw 
were then cloned into the pENTR™/D-TOPO
®
 vector (Life Technologies, Carlsbad, 
California USA) following instructions provided in the pENTR™ Directional TOPO
®
 
Cloning Kit (Life Technologies, Carlsbad, California USA).  
Following transformation, positive clones were selected using 100 µg/mL 
kanamycin agar plates and upscaled in LB broth for isolation of plasmid DNA. The 
presence of the gene insert was confirmed by PCR analysis using primers designed by 
Golde and colleagues (Golde et al. 1990). Plasmids that tested positive were sent for 
sequencing using the universal M13 Forward and Reverse primers and the following 
self-designed primers: TACCAACTTGCATGACTACGGCATG, 
TACGAAGAAGCCACAGAGAGAACCA, CTGGAGATCGTCCAGGCTGAAC. 
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Sequence verified plasmids were retained and used in subsequent LR cloning 
reactions. 
 
2.3.2 LR cloning 
LR cloning was subsequently performed to transfer the APP gene insert from 
the pENTR™/D-TOPO
®
 vector into the pcDNA6.2/V5-DEST expression vector (Life 
Technologies, Carlsbad, California USA) via a LR recombination reaction. The LR 
Clonase
™
 II enzyme mix (Life Technologies, Carlsbad, California USA) was used and 
the recombination reaction was performed based on instructions in the protocol 
provided. Positive clones were selected using 100 µg/mL carbenicillin agar plates and 
screened using colony PCR, before they were upscaled in LB broth for isolation of 
plasmid DNA. Plasmids were then sequence verified using self-designed primers 
before they were used for subsequent transfection experiments.         
 
2.4 Cell culture studies 
2.4.1 Maintenance of cell lines 
All cell lines used in this study were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% FBS, 5% sodium pyruvate and 5% PSA. 
They were subsequently maintained at 37°C in a humidified incubator supplied with 5% 
CO2.   
 
2.4.2 Generation of APP null (APP 
-/-
) neuronal cell lines 
The APP 
-/-
 neuronal cell line, APP 
-/-
-1 was isolated and immortalized as 
described by Tan and colleagues (Tan et al. 2008). From there, a neuronal cell line, 
APPKO deficient in glial fibrillary acidic protein but rich in microtubule associated 
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protein-2 (MAP2) was obtained by single cell dilution of the APP 
-/-
-1 cell line. To 
verify that APPKO was predominantly neuronal in nature, the cell line was subjected 
to western blot and RT-PCR analysis before transfection experiments were performed 
on the cell line.   
 
2.4.3 Killing curve of APP 
-/- 
cell lines 
Prior to transfection, a killing curve experiment was performed to determine 
the optimum concentration of blasticidin (Life Technologies, Carlsbad, California 
USA) that could kill all non-transfected cells within a week. To simulate conditions 
similar to transfection, cells were kept in antibiotic- and serum-free media for 24 
hours overnight and allowed to recover for 6 hours in normal DMEM before 
blasticidin was added. The selection media containing blasticidin was prepared from a 
10 mg/ml stock of blasticidin diluted in DMEM.  
Concentrations of blasticidin used were: 3µg/mL, 5µg/mL, 7.5µg/mL and 
10µg/mL. Culture media was changed once every 3 days and the extent of cell death 
was determined through visual inspection on a microscope for floating dead cells. 
Five µg/mL of blasticidin was found to be the optimum concentration of antibiotic for 
selection of stable cell clone as it resulted in a 100% cell mortality rate within a week 
of culture. Higher concentrations of blasticidin were not suitable as they killed the 
cells at a rapid rate resulting in complete cell death in less than 3 days after addition of 
the antibiotic.   
 
2.5 Stable transfection of cell lines 
A total of 5×10
4 
cells was seeded onto 6-well plates and maintained at 37°C in a 
humidified incubator supplied with 5% CO2 overnight. On the following day, cells 
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were transfected with Fugene
®
 6 transfection reagent (Roche, Basel, Switzerland) 
using 1 µg of plasmid DNA at a 3:1 Fugene
®
 6 reagent to DNA complex ratio. The 
transfection mixture was prepared in antibiotic- and serum-free media and left to 
incubate for half an hour at room temperature before it was added to the cells. Prior to 
transfection, culture media from the cells was removed and replaced with SFM. Cells 
were left for 24 hours overnight in the incubator to allow for transfection to take place. 
Subsequently, media containing the transfection mixture was removed and substituted 
with normal DMEM. The cells were then returned to the incubator and allowed to 
recover for 6 hours before selecting for positively-transfected clones.  
 
2.5.1 Selection of transfected cell clones 
DMEM containing 5 µg/mL of blasticidin was added to the cells and selection 
of stable cell clones was done for a week. Subsequently cells that survived the 
antibiotic selection were trypsinized and plated at descending serial dilutions of 2-fold 
each in 96-well microplates starting from a concentration of 250 cells per well and a 
final concentration of two cells per well. The cells were then cultured in maintenance 
media containing 2.5µg/mL blasticidin and the presence of isolated cell colonies were 
determined through visual inspection on a microscope.  
Cell colonies were allowed to grow for approximately 2 weeks in microwells 
before they were trypsinized and further cultured in 24-well plates. Once the cells 
reached 100% confluency, they were trypsinized and maintained in T-25 flasks. Half 
the contents of a confluent T-25 flask were frozen down and stored. The remaining 
half was upscaled for screening of protein expression using western blotting. 30 µg of 
proteins were used for analysis of APP expression in the cell clones.  
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A total of 30 over cell clones were screened and 2 positive clones (APP 
-/- 
695sw and 751sw) with equal APP expression were identified and used for subsequent 
downstream experiments. 
 
2.6 Biochemical assays 
2.6.1 Amplex red glucose assay 
For determination of the glucose content in the biological samples, the amplex 
red glucose assay kit (Life Technologies, Carlsbad, California USA) was used. Cell 
lysates were diluted 2-fold in the assay buffer supplied whereas tissue lysates were 
diluted at 10-fold initially in lysis buffer before a 2-fold dilution in assay buffer. A 
series of standards ranging from 0 to 100 µM of glucose were chosen to generate a 
standard curve. Generally, 50 µL of samples or standards was used for the assay. 
Equal volumes of amplex red working reagent were then added and the reaction 
mixture was then incubated for 30 minutes at room temperature in the dark before 
fluorescence values were measured. Fluorescence was read at an excitation 
wavelength of 535 nm and an emission wavelength of 590 nm using a Tecan 
microplate reader, M200 Infinite series (Tecan Group, Männedorf, Switzerland).  
 
2.6.2 Pyruvate assay  
Pyruvate concentrations in the samples were measured using a pyruvate assay 
kit (Biovision Inc, California, USA).  A confluent T-75 flask of cells was used for 
determination of intacellular pyruvate. Cells freshly scraped in PBS were lysed in 300 
µL of pyruvate assay buffer and centrifuged at 14,000×g for 10 minutes at 4°C. The 
soluble fraction was then collected and diluted two-fold in assay buffer for the 
assessment of pyruvate content. Similarly, previously diluted brain tissue lysates used 
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for the glucose assay were further diluted two-fold in assay buffer before 
measurement of pyruvate content. Standards for the assay were prepared following the 
manufacturer’s instructions. Fluorescence in the wells was then allowed to develop for 
30 minutes in the dark before values were read at excitation wavelengths of 535 nm 
and emission wavelengths of 590 nm. 
 
2.6.3 Lactate assay 
A lactate assay kit (Biovision Inc, California, USA) was used for determining 
the amount of lactate in the samples. The procedures used were similar to that of the 
pyruvate assay as described previously but with the following adjustments. First, 
RIPA buffer was used for cell lysis instead and second, cell lysates were diluted ten-
fold in lactate assay buffer supplied with the kit. The duration and conditions of 
incubation were unchanged and fluorescence values were read at the endpoint of the 
assay.  
 
2.6.4 ADP/ATP assay 
Cells were seeded in a 96-well microplate at a density of 1×10
4 
per well and 
allowed to settle and grow for a day. Prior to the start of the assay, they were washed 
and rinsed with PBS twice. Subsequently, cells were treated following instructions 
provided in the ADP/ATP ratio assay kit (Abcam, Cambridge, UK). Luminescence 
readings were obtained at different timepoints of the experiment as recommended by 
the vendor. The intracellular ADP/ATP ratio was then calculated based on an equation 
in the protocol provided. 
 





For quantification of the intracellular NAD
+
/NADH ratio, the NAD/NADH 
quantification assay kit (Biovision Inc, California, USA) was used. Briefly cells were 
seeded at a density of 1×10
5 
per well in a 6-well plate before the assay was performed 
the following day. They were then collected and scraped in 400 µL of ice-cold 
extraction buffer (provided in the kit) and lysed through repeated freeze-thaw cycles 
as recommended. Reactions were then carried out following instructions in the 
protocol provided before absorbance readings were measured at 450 nm. The 
NAD
+
/NADH ratio was then calculated as indicated in the protocol.     
 
2.7 Western blotting and ELISA 
2.7.1 Cell lysis 
For western blot analysis, cells were cultured in T75 flasks and harvested once 
they had reached confluency. In short, a cell scraper was used to dislodge the cells 
mechanically from the growth surface. Cells were then collected in ice-cold PBS and 
centrifuged at 500×g for 5 minutes to obtain a cell pellet. Following which, 300 µL of 
ice-cold 1× RIPA buffer (Cell Signaling Technology, Danvers, USA) with protease 
inhibitor tablet (Roche, Basel, Switzerland) was then added to the pellet. Cells were 
then resuspended in lysis buffer and the lysates were further sonicated twice under 
brief pulses of 10 seconds each to ensure thorough lysis. Lastly, lysates were 
centrifuged at 14,000×g for 10 minutes at 4°C to collect the soluble fractions. Lysates 
were then stored as aliquots in -80°C. 
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2.7.2 Tissue lysis 
Brain tissues snapped frozen in liquid nitrogen when harvested were used for 
lysis of the tissue samples. To ensure consistency in results, the whole left hemisphere 
of the frozen mouse brains was used. The wet weight of the tissues (in mg) was 
determined using an electronic balance and 1× cell lysis buffer (Cell Signaling 
Technology, Danvers, USA) with PI tablet was added at a 20% (weight: volume) ratio. 
Lysates were then homogenized using a PowerGen homogenizer (ThermoFisher 
Scientific, Waltham, USA) at 3 pulses of 20 seconds each, with a 10 second interval 
on ice in between to reduce excessive heat that was generated during homogenization. 
For subsequent downstream applications, tissue lysates were further diluted 10 times 
in cell lysis buffer and sonicated briefly to ensure complete lysis. 
 
2.7.3 Protein quantification of lysates 
Both cell and tissue lysates were quantified using the Pierce
™
 MicroBCA 
assay kit (ThermoFisher Scientific, Waltham, USA) in a 96-well microplate format. 
Lysates were diluted 15 times in PBS and the working reagent was prepared and 
added in accordance to the manufacturer’s instructions. Samples were then incubated 
at 37°C for 30 minutes before absorbance values were read at 562 nm on a Tecan 
microplate reader. Protein concentrations of samples were calculated based on a 
standard curve constructed from a range of BSA standards.  
 
2.7.4 SDS-PAGE and western blotting 
Lysates were added to a 4× loading buffer in a 3:1 (v/v) and heated at 95°C for 
5 minutes. Protein samples were then centrifuged at 14,000×g for 2 minutes on a 
benchtop centrifuge before they were loaded on a 7.5% Tris-glycine polyacrylamide 
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gel. The Precision Plus protein
™
 standard (Bio-Rad Laboratories, Hercules, California 
USA) was used as a molecular weight standard and run together with the samples on 
the same piece of gel. For most of the gels, 30 µg of protein was loaded per lane 
unless otherwise stated. 
For electrophoresis of all protein gels, the Mini-PROTEAN Tetra 
electrophoresis system (Bio-Rad Laboratories, Hercules, California USA) was used. 
Briefly, samples were allowed to run at 70 V across the stacking gel for approximately 
half an hour. The voltage of the system was further increased to 100 V when the dye 
front of the samples reached the top of the resolving gel. Electrophoresis was 
continued until the dye front of the samples had reached the bottom of the protein gel. 
The gel was then removed and proteins were transferred onto a nitrocellulose 
membrane using the Mini Trans-Blot cell (Bio-Rad Laboratories, Hercules, California 
USA).  Protein gel transfers were either performed overnight at 27 V or for 90 minutes 
at 100 V. The blot was then removed and efficiency of the transfer was verified using 
Ponceau S (Sigma-Aldrich, St-Louis, USA) staining. 
The Ponceau S was then washed off the blot using PBST (PBS with 0.1% 
Tween 20) before it was blocked under gentle agitation for 30 minutes with 5% non-
fat milk (in PBST). The blot was then washed twice in PBST for 5 minutes each. 
Subsequently, it was incubated overnight at 4°C in primary antibody under gentle 
agitation. Following that, the blot was washed thrice in PBST at 10 minutes each time. 
HRP-conjugated secondary antibody corresponding to the species which the primary 
antibody was raised in was then added. The blot was then incubated in secondary 
antibody (dissolved in 3% non-fat milk in PBST) for 90 minutes at room temperature 
under gentle agitation. Finally, the blot was washed thrice in PBST before developing 
it in chemiluminescence.  
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Generally, two different substrates were used for chemiluminescence detection 
on the blots. In most instances, the SuperSignal West Dura substrate (ThermoFisher 
Scientific, Waltham, USA) was used and the blot would be exposed for approximately 
2 minutes. However if the signal generated was weak, then the SuperSignal West 
Femto substrate would be used and coupled with a shorter exposure time of 30 
seconds. All the blots were developed using the Image Station 4000R (Carestream 
Health Inc, New York, USA).  
 
2.7.5 Concentration of protein from media 
Proteins in cell culture media were concentrated using two different sets of 
centrifugal filter units. Prior to that, existing media from culture flasks was removed 
and replaced with serum-reduced media containing 0.2% of FBS. Cells were then 
grown in serum-reduced media for 16 to 18 hours to allow for the accumulation and 
enrichment of secreted proteins. Culture media was then removed and protease 
inhibitors were added before concentration of proteins.   
The media was first concentrated using an Amicon Ultra-0.5 Centrifugal Filter 
with 30kDa cutoff (Millipore, Massachusetts, USA) by centrifugation at 14,000×g for 
10 minutes. Both the filtrate and concentrate were retained. The concentrate was 
quantified and used for western blot analysis of secreted proteins. Consequently, the 
filtrate was further concentrated using an Amicon Ultra-0.5 Centrifugal Filter with 
3kDa cutoff (Millipore, Massachusetts, USA) by centrifuging at 14,000×g for 30 
minutes. The resulting concentrate obtained was then used for ELISA analysis. To 
remove residual protein that could have adhered to the centrifugal unit, a small 
volume of RIPA buffer was used to rinse the filter unit membrane.     
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2.7.6 Insulin ELISA 
The human insulin ELISA kit (Millipore, Massachusetts, USA) was used for 
quantification of insulin. Following manufacturer’s instructions, 10 µL of protein 
concentrate from media or cell lysate was used for analysis of secreted and 
intracellular insulin respectively. After addition of the substrate and stop solution, the 
microplate was then read at 450 nm on a Tecan microplate reader.  
 
2.7.7 Aβ ELISA 
2.7.7.1  Aβ extraction from mouse brain extracts 
Brain lysates were diluted 500-fold in ice-cold 5M guanidine hydrochloride, 
pH 8. The resulting mixtures were then incubated at room temperature with vigorous 
shaking at 450 rpm for 3 hours at room temperature. Subsequently, the guanidine-
treated samples were then further diluted 100 times in EIA buffer (supplied in the Aβ 
ELISA kit) before they were used for Aβ quantification.     
 
2.7.7.2 Aβ ELISA assay 
The amount of secreted extracellular Aβ was quantified using the Human 
Amyloidβ (1-40) (N) Assay Kit and the Human Amyloidβ (1-42) (N) Assay Kit 
(Immuno-Biological Laboratories Co., Ltd, Gunma, Japan).  For quantification of 
Aβ42, protein concentrates from the culture media were loaded neat. However for the 
quantification of Aβ40, samples were diluted two times in the EIA buffer provided. 
Subsequently, samples were processed as stated in the protocol and readings were 
taken at 450 nm on a Tecan microplate reader within half an hour after addition of the 
stop solution. 
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For quantification of Aβ in mouse brain lysates, 150 µL of guanidine treated 
samples (diluted in EIA buffer) were loaded per well and the ELISA assay was 
performed as per the instructions stated in the manufacturer’s kit.     
       
2.8 Real-time PCR analysis 
2.8.1 Isolation of total RNA 
RNA extraction for both cells and tissues was done using TRIzol
®
 reagent 
(Life Technologies, Carlsbad, California USA). In general, less than 50 mg of brain 
tissue was used which was then homogenized in 500 µL of TRIzol
®
 reagent with a 
handheld homogenizer (ThermoFisher Scientific, Waltham, USA). To ensure 
complete lysis of tissue, the resulting lysate was further homogenized by 10 passages 
through a 22G needle. The lysate was then processed following manufacturer’s 
instructions provided in the material datasheet up to the RNA precipitation stage.   
For isolation of RNA from cells, a confluent T-25 flask of cultured cells was 
used. Cells were scraped and harvested in 1×PBS, which was followed by a 
centrifugation step to yield a cell pellet. Similarly, 500 µL of TRIzol
® 
reagent was 
used for the homogenization step and samples were processed in the same manner as 
the tissue samples. For both cell and tissue samples, the precipitated RNA fraction 
was subjected to an additional clean-up step using the RNeasy Mini kit (Qiagen, 
Hilden, Germany). RNA samples were typically eluted twice in 40 µL of RNase free 
water provided in the kit before they were quantified using the Nanodrop
™
 2000.  
 
2.8.2 Reverse transcription of RNA 
RNA samples were reverse transcribed using the Reverse Transcription system 
(Promega, Madison, USA). Typically, 1 or 2 µg of RNA was processed each time. 
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The RNA was first heated at 70°C for 10 minutes and placed on ice before mastermix 
containing reverse transcriptase was added. The resulting mixture was then incubated 
at 42°C for 20 minutes to allow for cDNA synthesis. Lastly, the cDNA was heated at 
95°C for 5 minutes and placed on ice for another 5 minutes to inactivate the reverse 
transcriptase enzyme.  
 
2.8.3 Real-time PCR 
Each real-time PCR reaction was performed using 200 ng of cDNA. Samples 
were run in duplicates in volumes of 20 µL each. Specific TaqMan
®
 probes (Life 
Technologies, Carlsbad, California USA) were used for the detection of various gene 
products. A typical reaction setup consists of the following components:  
Component Volume (µL) 
2× TaqMan® Gene Expression Master Mix 10 
20× TaqMan® probe 1 
Nuclease free water 7 
cDNA 200ng 
Total volume  20 
 
Reactions were then run in a 96-well format on a StepOnePlus
™
 Real-time 
PCR system (Life Technologies, Carlsbad, California USA) using the default cycling 
conditions. For each real-time PCR, a minimum sample size of n=3 was used and each 
sample was run in duplicates to ensure accuracy. Statistical analysis of the results was 
done using the Student’s t-test. 
 





The expression level of the following genes (and the TaqMan Gene Expression 
Assay catalogue) was investigated using real-time quantitative PCR and TaqMan 
probe-based chemistry (Life Technologies, Carlsbad, California USA). Most of the 
genes listed correspond to targets in the mouse genome unless otherwise stated. 
Citrate synthase (Mm00466043_m1), cytochrome c oxidase (Mm01250094_m1), 
human APP (Hs01552283_m1), human APP695 (Hs01562345_m1), human APP751 
(Hs01562342_m1) isocitrate dehydrogenase (Mm00612429_m1), succinate 
dehydrogenase (Mm00458268_m1) and β-actin (Mm00607939_s1). These probes 
span the exon(s) of the targeted genes and the assays were performed based on the 
manufacturer’s instructions. 
 
2.9 Isolation of mitochondria 
Mitochondria were isolated from a confluent T-75 flask of cultured cells using 
the Mitochondria Isolation kit for cultured cells (ThermoFisher Scientific, Waltham, 
USA). Briefly cells were scraped and collected in ice-cold PBS. They were then 
centrifuged at 400×g for 5 minutes to obtain a cell pellet. Cells were then processed 
following instructions in the provided protocol up till the homogenization step. 
Subsequently, the cell suspension was homogenized by performing 30 passes through 
a 27G needle on ice. To ensure complete lysis, a portion of the cell lysate was 
examined under the microscope to check for rupture of the plasma membrane.  
Samples were further processed as per manufacturer’s instructions with the 
mitochondrial pellet obtained by centrifuging the suspension at 3000×g for 15 minutes 
at 4°C. The ensuing cytosolic supernatant was retained for further analysis. Following 
which, the pellet was washed once using 500 µL of Mitochondria Isolation Reagent C 
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(provided in the kit) and centrifuged at 12,000×g for 5 minutes at 4°C to obtain a 
purified mitochondrial fraction. The reagent was then removed leaving a small amount 
behind for resuspension of the mitochondrial pellet into a paste. The mitochondrial 
fraction was then kept on ice for downstream analysis. For assessment of isolation 
efficiency, both the cytosolic and mitochondrial fractions were analysed using western 
blot by probing for mitochondrial markers.  
 
2.10 COX IV activity assay 
Isolated mitochondria fractions were quantified using the Pierce
™
 MicroBCA 
assay kit and the Cytochrome c Oxidase assay kit (Sigma-Aldrich, St-Louis, USA) 
was used for the subsequent measurement of COX IV activity. For each assay, 20 µg 
of mitochondrial protein was used. Reactions were set up as per stated in the protocol 
and absorbance readings were taken at 10 second intervals for 6 consecutive reads at 
550 nm. A blank containing only 100 µL of enzyme dilution buffer was also included 
to normalize changes in absorbance values due to the enzyme dilution buffer alone. 
The COX IV activity was then calculated using the equation provided in the protocol 
and expressed in terms of units per ml. 
All reactions were run in triplicates and performed in a 24-well plate format. 
Absorbance values were recorded immediately on a Tecan microplate reader 
following orbital shaking of the microplate after addition of the reduced 
ferrocytochrome c substrate. 
 
2.11 Measurement of mitochondrial membrane potential 
The JC-1 dye was used for the measurement of mitochondrial membrane 
potential. Briefly, 2×10
4
 cells were seeded per well in a black microplate and allowed 
 43 | P a g e  
 
to settle for a day before the assay was performed. Subsequently, 10 µM of JC-1 in 
100 µL of Earle’s balanced salt solution (EBSS) was added to each well and left to 
incubate for 30 minutes at 37°C. The cells were then washed twice in EBSS before 
fluorescence values were measured. Two separate reads were performed. One read 
was done to measure green fluorescence at an excitation wavelength of 488 nm and an 
emission wavelength of 590 nm; while another measured the red fluorescence at an 
excitation wavelength of 560 nm and an emission wavelength of 595 nm. The ratio of 
the red to green fluorescence was then calculated to determine the mitochondrial 
membrane potential.     
 
2.12 H2DCFDA assay 
The H2DCFDA assay measures the amount of reactive oxygen species (ROS) 
produced by cells. For this assay, the carboxy-H2DCFDA dye (Life Technologies, 
Carlsbad, California USA), which fluoresces when oxidized by ROS was used as an 
indicator of the amount of ROS present. A procedure similar to that used for the 
mitochondrial membrane potential assay was adopted. However, only one single 
fluorescence read was measured at the end of the assay using an excitation wavelength 
of 495 nm and an emission wavelength of 520 nm.   
     
2.13 Caspase-3 activity assay 
For the measurement of caspase-3 activity, the Caspase-Glo
®
 3/7 Assay 
System (Promega, Madison, USA) was used. Briefly, 1×10
4
 cells were seeded per 
well in a white microplate and allowed to settle for a day before cells were assayed for 
caspase-3 activity. The assay was then performed following manufacturer’s 
instructions and luminescence values were recorded at an hourly interval for 4 hours. 
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Generally, the amount of luminescence produced usually reaches a maximum value 
before 2 hours after addition of the substrate. Luminescence values obtained (in 
relative luminescence units, RLU) were normalized against that of mock cells to 
calculate the percentage activity of caspase-3 in the respective cell lines.   
    
2.14 Flow cytometry  
For each flow cytometry run, approximately 5×10
5
 of cultured cells was used. 
Briefly cells were detached by incubation in PBS-based cell dissociation solution 
(Life Technologies, Carlsbad, California USA) and centrifuged at 400×g for 5 minutes 
to obtain a cell pellet.  
Cells were then washed once before they were incubated in primary antibody 
for 45 minutes at room temperature. Primary antibodies were diluted at 1:250 in 0.1% 
BSA in PBS.  Subsequently, cells were washed before incubation with secondary 
antibody. For detection of antigen binding by primary antibody, secondary antibodies 
conjugated to an Alexa Fluor
®
 488 dye were used (Life Technologies, Carlsbad, 
California USA). The choice of secondary antibody used was dependent on the 
species in which the primary antibody was raised in.  
The same buffer used in the incubation steps for both primary and secondary 
antibodies was also used for the washing steps in between. In addition for each type of 
secondary antibody used, a blank was included that comprised of cells that were 
incubated with only secondary antibody. The purpose of including a blank was to 
eliminate non-specific binding due to the secondary antibody in subsequent 
calculations of the fluorescent signal generated by the bound secondary antibody. 
Likewise, cells were incubated in secondary antibody under the same 
conditions as that of the primary antibody incubation. The only exception was that the 
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secondary antibody incubation was done in the dark. Finally, cells were washed twice 
before they were resuspended in 300 µL of 0.1% BSA in PBS. They were then kept 
on ice before analysis on a BD FACSCalibur Flow cytometer (BD Biosciences, 
California, USA). A total of 2×10
4
 events were analysed. 
 
2.15 Immunofluorescence staining 
Cells were seeded at a density of 1000 cells per well on sterile glass coverslips 
placed in a 24-well microplate and cultured for a day before they were fixed in 4% 
paraformaldehyde (in PBS) for 20 minutes. Subsequently, 3 washes of PBS were 
performed before cells were permeabilized in 0.1% Triton-X 100 (in PBS) for 10 
minutes. Following that, cells were blocked in 3% BSA (in PBS) after 3 washes with 
PBS. In this protocol, all the washing steps in PBS lasted for about 5 minutes.   
After blocking, cells were washed thrice in PBS again before they were 
incubated with primary antibodies (diluted at 1:100 in blocking buffer) overnight at 
4°C. The primary antibody was then removed, and cells were washed with PBS again 
before Alexa Fluor
®
 488 conjugated secondary antibodies were added (diluted at 
1:200 in blocking buffer). Cells were then incubated in secondary antibody for 90 
minutes at room temperature before removal of the secondary antibody. After washing 
the cells thrice in PBS, coverslips were removed and sealed in SlowFade
®
 Gold 
antifade reagent (Life Technologies, Carlsbad, California USA) before being viewed 
on the microscope. The same exposure time was used to capture all the fluorescent 
images.          
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3. Characterization of APP transfected cell lines 
3.1 Introduction 
Transfected cell lines have been widely employed in various studies to 
investigate the functions of different proteins. Similarly, many cell lines have also 
been used in expression studies of APP to examine unique functional aspects of APP. 
Therefore, we created an immortalized APP knock-out mouse neuronal cell line for 
our work in elucidating APP-related changes occurring in a specific subset of cells. 
Before proceeding with my transfection studies, we further isolated a neuronal rich 
population of cells with positive MAP2 expression. Subsequently the cell line was 
transfected with two different APP isoforms and characterized to ensure that they 
expressed comparable levels of protein.  
Swedish mutant constructs of APP were used as the Swedish mutation in APP 
(Mullan et al. 1992) is known to promote the formation of Aβ (Perez et al. 1996). 
Specifically, in the Swedish mutation of APP, there is a double amino acid 
substitution at amino acid residues 670 and 671 (based on the amino acid sequence in 
APP770) from a lysine (Lys) to asparagine (Asn) and a methionine (Met) to a leucine 
(Leu) respectively. As such, using Swedish APP mutant constructs will allow me to 
mimic the conditions in AD in which there is an increased production of Aβ, coupled 
with an increase in the amount of KPI-positive APP isoforms. In addition, mock cells 
that had been stably transfected with an empty plasmid were also included as a control.          
 
3.2 Results 
3.2.1 Expression profile of APP in the transfected cell lines 
Stable cell clones obtained were subjected to real-time PCR analysis for 
detection of the human APP (hAPP) gene transcripts. As expected, no hAPP gene 
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transcript was detected in the mock cells (Fig. 3.1). On the other hand, a large amount 
of hAPP gene transcript was observed in both APP transfected cell lines, APP695sw 
and APP751sw. However, no significant difference in the level of the hAPP gene 
transcript was detected when both APP transfected cell lines were compared.  
In order to validate the specific APP isoform expressed by both transfected cell 
lines, further real-time PCR analysis was performed using probes that were specific to 
either the APP695/751 protein isoform. Expectedly, only a single APP isoform was 
detected in each of the transfected cell lines corresponding to the identity of the 
transfected protein isoform (Fig. 3.1b). 
 
Figure 3.1 Equal and specific expression of APP mRNA transcripts in both APP695sw and 
APP751sw cell lines. 
 
(a) Relative quantification of hAPP expression level in cell lysates using real time RT-PCR (b) Relative 
quantification of hAPP695 and hAPP751 expression level in cell lysates using real time RT-PCR. The 
expression of each target gene was quantified relative to the endogenous β-actin level for each sample. 
Each value represents the mean ± SEM of duplicate assays for individual samples (n = 3 each). 
Significant differences were observed in the expression level of the target genes determined in both 
APP-transfected cell lines relative to that in mock cells. Additionally, the gene expression in each of the 
APP-transfected cell line corresponded to that of a specific APP isoform, namely APP695sw and 
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APP751sw respectively. The probe IDs for the respective protein isoforms are listed in the Materials 
and Methods section.   
 
Subsequently, immunoblotting analysis was carried out to probe for the 
presence of APP in the cell lysates. Prominent bands of similar intensity and thickness 
corresponding to APP were detected in 30 µg of cell lysates analysed (Fig. 3.2a). A 
thin band corresponding to non-specific binding of the antibody was also detected in 
mock cells that were confirmed to be devoid of the hAPP gene transcript in figure 3.1. 
Also, an actin immunoblot was included to show equal loading of protein in all lanes. 
Subsequently, an immunofluorescence analysis of the cell lines was performed, which 
confirmed the intracellular presence of the APP protein within both APP695sw and 
APP751sw cell lines (Fig. 3.2b).  
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Figure 3.2 Equal and comparable expression of APP in both APP-transfected cell lines.  
 
(a) Immunoblotting analysis of APP levels in cell lysates. β-actin was immunoblotted to ensure similar 
gel loading of the starting material in each sample. sAPP derived from both the amyloidogenic and non-
amyloidogenic processing of APP was detected using anti-22C11 (recognizes amino acids 66-81 at the 
N-terminus of APP) while sAPPβ, derived from the amyloidogenic processing of APP was detected 
using anti-6E10 (that recognizes amino acids 1-17 of the Aβ domain on APP). (b) Immunofluorescence 
staining of cell lines.  Anti-6E10 was used at a dilution factor of 1:250 to probe for the presence of 
intracellular APP. A DAPI staining was also included to show that the integrity of the cells was not 
compromised during the staining process.       
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3.2.2 APP processing and differential generation of Aβ by both APP-
transfected cell lines 
Subsequently after verifying the presence of APP at both the mRNA and 
protein level in the cell lines, the culture media from both transfected cell lines was 
analysed for the presence of the protein. As described previously in section 1.2.2 on 
APP processing, APP can be proteolytically processed to generate the soluble version 
of the protein, sAPP that is secreted into the culture media. Proteins present in the 
culture media from mock and APP-transfected cell lines were concentrated and 
subjected to immunoblot analysis. Similar to the cell lysates, two protein bands 
corresponding to the APP695sw isoform and the APP751sw isoform were observed 
respectively (Fig. 3.3a). To ensure a fair comparison, equal amounts of protein were 
loaded per lane for analysis. 
Following that, the proteolytic processing of APP to Aβ in the cell lines was 
examined. Briefly, Aβ is produced and secreted when APP is cleaved sequentially by 
β- and γ-secretase within the cell. The Aβ present in the concentrated culture media 
from the neuronal cell lines was quantified using a sensitive ELISA kit. A significant 
difference in the amount of Aβ40 and Aβ42 produced (*p < 0.05 and *p < 0.01 
respectively) was detected between APP695sw cells and APP751sw cells. Generally, 
APP695sw cells produce more Aβ than APP751sw cells (Fig. 3.3b). 
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Figure 3.3 APP is processed proteolytically to generate secreted forms of the protein and Aβ that 
are detected in the media of cultured cells. 
 
(a)Immunoblotting analysis of proteins concentrated from the media of cultured cell lines. 30µg of 
protein was loaded per lane and anti-6E10 was used to probe for the presence of APP (b) Relative 
quantification of Aβ40 and Aβ42 using ELISA performed on proteins concentrated from the culture 
media. Each value represents the mean ± SEM of assays for individual samples (n = 3 each). 
Significant differences were observed in the Aβ levels between APP695sw and APP751sw (*p < 0.05; 
**p < 0.01 using Student’s t-test).   
                                 
3.3 Discussion 
Immortalized APP knock-out neuronal cells were used for this study as it 
would allow for the characterization of the individual effect attributed by each APP 
isoform transfected into the cell line. This was a novel approach as most published 
work on APP use commercially available cell lines that contain endogenous forms of 
APP. By doing so, any effect that endogenous APP might exert on the different 
parameters of energy homeostasis studied will be effectively eliminated. Additionally, 
this would also reduce any overexpression effect that APP might cause since the 
endogenous source of the protein would have been removed.   
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As mentioned, mock cells that were stably transfected with an empty plasmid 
were included in this analysis as a control for subsequent studies. The decision to use 
mock cells as a normal control was based on a previous finding that showed no 
involvement of APP in regulating cell survival in neurons isolated from APP null 
mice (White et al. 1998). Thus this would allow the effects of different APP isoforms 
on energy metabolism to be examined under conditions in which cell survival was not 
compromised. 
A protein band of a higher molecular weight in APP751sw cells was 
consistently observed in immunoblots of cell lysates from APP751sw cells. This was 
expected since APP751sw contains an extra KPI domain compared to APP695sw, 
which causes it to have a higher molecular weight and to migrate at a slower rate than 
APP695sw. The detection of sAPP in the culture media of both APP transfected cells 
is also in line with results from previous studies conducted on APP trafficking in other 
cell lines (Wang et al. 1991). This finding suggests that in the neuronal cell line used 
in this study, APP undergoes processing through the secretory pathway and is cleaved 
by α- or β-secretase before it is secreted into the extracellular media.  
Further, the presence of sAPP in the intracellular fraction was also confirmed, 
which validates the normal proteolytic processing of APP in the neuronal cell lines 
used. For this study, it was crucial to verify that the cell lines can synthesize and 
process APP. This would not only ensure that the immortalized cell line used is a 
suitable candidate for expressing APP but it would also ensure that subsequent results 
from downstream experiments would be an accurate representation of the 
physiological effect caused by different APP isoforms. 
Two antibodies were used in the detection of sAPP in the cell lysates. In 
particular, the 22C11 antibody clone was found to identify a thicker and denser 
 53 | P a g e  
 
protein band than the 6E10 antibody clone. This was expected since the 22C11 clone 
recognizes the N-terminus of APP, which allows it to detect both sAPPα and sAPPβ 
species. This was in contrast to the 6E10 clone which only recognizes sAPPα since it 
binds to amino acid residues 1-17 of the Aβ domain, which is situated after the β-
secretase cleavage site. Therefore these results obtained further confirm that the α- and 
β-secretase in the neuronal cell lines used are capable of recognizing the transfected 
human APP construct and cleaving it to produce sAPP as described earlier. 
Interestingly in the course of the studies, a differential ability of the APP 
isoforms to generate Aβ was found. In particular, the relative amount of extracellular 
Aβ produced by each APP isoform differed from that published previously in which 
non-neuronal cell lines were used (Ho et al. 1996). Contrary to Ho and colleagues, the 
KPI-containing APP751sw isoform was found to produce less Aβ than the APP695sw 
isoform. Since both cell lines produce equal and comparable amounts of total sAPP 
suggesting that the activity levels of α- and β-secretase are likely to be the same 
between both cell lines; it is possible that the different amounts of Aβ produced are 
due to differences in the γ-secretase activity of the APP695sw and APP751sw cell 
clones instead, with APP695sw cells having higher γ-secretase activity levels.    
This finding implies that APP isoforms most probably display different 
processing profiles depending on the cellular background in which the protein was 
expressed in. These observations are also in line with a recent study that 
overexpressed APP in neuronal cell lines, which reported a similar trend in Aβ 
production that further confirms my results (Belyaev et al. 2010). In addition, the ratio 
of Aβ40 to Aβ42 generated was also similar to that reported by Tan and colleagues 
(Tan et al. 2008), who made use of unsorted neuronal cell lines of the same genetic 
background to overexpress APP695sw.       
 54 | P a g e  
 
Taken together, the results confirm that there is similar expression level of 
APP both at the gene and protein level in the transfected neuronal cell clones. The 
presence of both sAPP and Aβ in the culture media of the cell lines suggests that the 
immortalized mouse neuronal cell line used in this study is ideal for overexpressing 
APP since it allows the normal proteolytic processing of the protein. The subsequent 
chapters will focus on the role of different APP isoforms in the regulation of energy 
metabolism.                              
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4. APP isoforms modulate glucose metabolism differentially in neuronal 
cells 
4.1 Introduction 
Previous studies using knockout animals have demonstrated a plausible role of 
APP in maintaining blood plasma glucose levels (Needham et al. 2008). Additionally, 
our lab has also found a preliminary correlation between APP and brain glucose from 
biochemical analysis of APP null (APP
-/-
) and wildtype mouse brains. Specifically, a 
consistent depreciation of brain glucose in APP
-/- 
mice was observed throughout aging 
(unpublished observations). Since glucose metabolism is important in ensuring normal 
brain activity and the function of APP in the brain with regard to glucose metabolism 
has yet to be fully established, it was of interest to determine if and how different 
isoforms of APP may modulate changes in the glucose content of neuronal cells. I 
hypothesize that APP is likely to exert a regulatory effect on brain glucose content and 
metabolism, which is dependent on the type of APP isoform present.  
 
4.2 Results 
4.2.1 APP expression causes an increase of the free glucose levels  
The intracellular glucose content of the neuronal cell lines described and 
characterized in the previous chapter was measured using lysates of these cell lines. 
There was a marked elevation in the free glucose content of APP695sw cells as 
compared to mock or APP751sw cells (Fig. 4.1). Also, a slight increase in the free 
glucose content of APP751sw cells was observed as compared to mock cells (*p <0.1). 
This suggests that when the cellular expression of APP is restored, there is a 
corresponding increase in the amount of free glucose present in the cells. However 
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this increase in glucose content seems to be dependent on the type of APP isoform 
present.     
 
Figure 4.1 Amplex red glucose assay of the intracellular glucose content in neuronal cell lysates. 
  
For each sample, the absolute amount of glucose detected was normalized against the protein 
concentration of the cell lysates to obtain a relative concentration. Each value represents the mean ± 
SEM of duplicate assays for individual samples (n = 3 each). A significant difference in the glucose 
content was observed between APP695sw cells and APP751sw cells (***p<0.001 using Student’s t-
test). There was also a significant difference in the glucose content between APP695sw cells and mock 
cells (*** p<0.001 using Student’s t-test). 
 
Next, I was interested to examine if such a change in cellular glucose content 
could also be attributed to differences in the amount of Aβ produced by the cell lines. 
In particular, the addition of Aβ42 to culture media has been reported to induce 
glucose uptake in cultured neurons (Soucek et al. 2003). Since it was established in 
the previous chapter that APP695sw neuronal cells produce more Aβ than APP751sw 
cells, it is likely that the increase in free glucose in APP695sw cells could also be 
caused by the higher amount of Aβ secreted into the media by the cell line.  
Subsequently, I incubated mock cells in conditioned media from mock, 
APP695sw or APP751sw neuronal cell lines respectively for 6 hours and measured 
the free glucose content. There was no obvious fold-change in the free intracellular 
glucose content of mock cells that were cultured in either of the APP-transfected 
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neuronal cell conditioned media (Fig. 4.2a). This was in direct contrast to the 
significant fold-change in free glucose content detected in both APP transfected cell 
lines that expressed APP (Fig. 4.2b). Taken together, the results suggest that the 
increment in free glucose content was largely dependent on the intracellular 
expression of APP rather than the differential amount of Aβ generated by the APP-
transfected neuronal cell lines. 
 
Figure 4.2 Alteration in cellular glucose content is not dependent on the amount of Aβ present in 
the culture media. 
 
(a)Relative fold change in glucose content of mock cells that were incubated for 6 hours in conditioned 
media from mock cells, APP695sw cells and APP751sw cells respectively. (b) Relative fold change in 
glucose content of mock, APP695sw and APP751sw cells cultured in normal media. Each value 
represents the mean ± SEM of duplicate assays for individual samples (n = 3 each). For each sample, 
the relative fold change in glucose concentration was calculated by normalizing against the glucose 
concentration of mock cells. No significant difference was found between the glucose concentration of 
mock cells treated with conditioned media from both APP transfected cell lines and conditioned media 
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of mock cells. However, a significant difference in the relative fold change of glucose content was 
observed between APP695sw cells and APP751sw cells, as well as APP695sw cells and mock cells 
(*** p<0.001 using Student’s t-test).   
 
4.2.2 Increased GLUT-3 expression in APP695sw cells 
Since an increase in intracellular glucose can potentially be mediated by an 
increased expression of glucose transport molecules that would facilitate the diffusion 
of glucose across the cell membrane, it was of interest to investigate if there were any 
alterations in the expression of the major brain glucose transporter – GLUT-3. The 
reason for selecting this particular GLUT isoform for analysis was based on previous 
findings that demonstrated its predominant expression in primary cultured neurons 
(Maher & Simpson 1994). As such, it is likely that an increase in GLUT-3 expression 
could have contributed to the marked elevation of intracellular glucose in the APP 
transfected cell lines, in particular APP695sw cells. As expected, immunoblotting 
analysis revealed a marked elevation of GLUT-3 protein expression in APP695sw 
(Fig. 4.3a), which corresponded to the high intracellular glucose content of the cell 
line.  
Subsequently, a flow cytometric analysis of GLUT-3 surface expression was 
performed to determine if there was also an increase in the amount of GLUT-3 on the 
cell surface. Using mock cells as a baseline, it was found that both APP-transfected 
cells exhibited a slight upregulation in GLUT-3 surface expression (Fig 4.3b). There 
was approximately 1.2-fold more GLUT-3 on the cell surface of both APP695sw and 
APP751sw cells as compared to mock cells. 
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Figure 4.3 Increased GLUT-3 protein and surface expression in APP695sw cell lines. 
 
(a)Immunoblotting analysis of GLUT-3 protein expression in cell lysates. For each sample, 30 µg of 
protein was loaded per lane and beta actin was included as a loading control. (b) Flow-cytometric 
analysis of GLUT-3 surface expression on cell lines. Fluorescent values measured were analysed using 
the CellQuest software, and values obtained were normalized against that of mock cells to generate 
relative percentages of receptor expression on the cell surface.  
  
4.2.3 Increased glycolysis in APP695sw cells compared to APP751sw cells 
Other than examining ways in which glucose uptake could have been affected, I 
was also interested in determining if changes in the intracellular glucose content could 
have been a result of a diminished breakdown of glucose to pyruvate during glycolysis. 
Therefore, the free pyruvate content in the cell lysates was tested. Generally, the cell 
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lines displayed a similar trend in pyruvate content as that observed earlier in the free 
cellular glucose content. In particular, a largely significant increase in free pyruvate 
was detected in APP695sw cells as compared to either mock or APP751sw cells (Fig. 
4.4a), suggestive of an increase in glycolysis. On the other hand, no significant 
difference was found when comparisons were made between the pyruvate 
concentration of mock and APP751sw cells.  
Since the conversion of pyruvate to lactate during anaerobic glycolysis can 
also cause depletion in pyruvate levels, the lactate content of the cell lines was also 
examined to determine if changes in anaerobic glycolysis had contributed to the 
observed changes in pyruvate content. A quick glance across the results showed no 
significant variation of lactate concentration among the 3 different cell types (Fig. 
4.4b). Hence it is unlikely that the observed changes in pyruvate concentration could 
be due to differences in the conversion rate of pyruvate to lactate. Essentially if the 
former was true, a major decline in lactate content would have been detected in 
APP695sw cells while mock and APP751sw cells would possess much higher lactate 
levels. For both assays, the same batch of lysates was used, with normalization of data 
performed using the protein concentration of the respective cell lysates to ensure a fair 
comparison among samples. 
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Figure 4.4 The increase in pyruvate concentration of APP695sw cells was not mediated by 
differences in the conversion rate of pyruvate to lactate. 
 
(a) Quantification of the free pyruvate content in neuronal cell lysates. (b) Quantification of the free 
lactate content in the same batch of neuronal cell lysates. For each sample, the absolute amount of 
glucose or pyruvate detected was normalized against the protein concentration of the lysates to obtain a 
relative concentration of metabolite. Each value represents the mean ± SEM of duplicate assays for 
individual samples (n = 3 each). A significant difference in the pyruvate content was observed between 
APP695sw cells and APP751sw cells (*p<0.05 using Student’s t-test). No difference in lactate content 
was observed between all 3 cell lines.   
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4.2.4 High glucose and pyruvate levels are associated with increased 
mitochondrial activity in APP695sw cells 
An increase in glycolysis has also been associated with a shift in the mode of 
energy production from mitochondrial respiration to glycolysis in neurons under high 
oxidative stress (Liu et al. 2006). Such a process would not only serve to maintain 
ATP levels in the cell, but produce large amounts of pyruvate as well. Since there was 
increased glycolysis and pyruvate content in the APP695sw neuronal cell lines, I 
sought to explore the association between the seemingly high glucose and pyruvate 
content of the APP695sw neuronal cell lines with the intrinsic mitochondrial activity 
of the cells. Therefore, a measurement of the NAD
+
/NADH ratio in the cultured cell 
lines was performed.  
The NAD
+
/NADH ratio is determined largely by the activity of the complex I in 
the electron transport chain of the mitochondria, which converts NADH to NAD+ via 
an oxidation reaction. Electrons generated from the oxidation of NADH would be 
transferred via the complexes in the electron transport chain (ETC) of the 
mitochondria to oxygen, reducing it to water.  This transport of electrons is coupled to 
proton pumping across the complexes, which produces a membrane potential across 
the mitochondria, contributing to the protonmotive force required for ATP production. 
As such, a high NAD
+
/NADH ratio might be indicative of an increased mitochondrial 
activity and vice versa. There was a considerably marked increase in the 
NAD
+
/NADH ratio in APP695sw cells as compared to APP751sw or mock cells (Fig. 
4.5a). However, there was no significant difference in the NAD
+
/NADH ratio between 
mock and APP751sw cells. 
Following that, the mitochondrial membrane potential, ∆ψ
m
 of the neuronal cell 
lines was determined using the cationic fluorescent dye, JC-1. This particular dye is 
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concentrated by mitochondria in proportion to their ∆ψ
m
.
 It exists as a monomer that 
fluoresces green and forms J-aggregates producing red fluorescence at low and high 
∆ψ
m
 respectively. An increased activity of the mitochondrial complexes in the ETC 
would result in increased protons being pumped across the mitochondrial membrane; 
thus causing a high electrical potential difference (in this case the mitochondrial 
membrane potential, ∆ψ
m
) across the mitochondrial membrane. As expected, there 
was a significant increase in the mitochondrial membrane potential measured in 
APP695sw cells compared to APP751sw cells that corresponded to its high 
NAD
+
/NADH ratio (Fig. 4.5b). 
Subsequently, mitochondria were isolated from the cell lines and the activity of 
cytochrome c oxidase (COX IV) in the mitochondria was measured using equal 
amounts of mitochondrial protein. Not surprisingly, APP695sw cells showed a 
significantly elevated COX IV activity (Fig. 4.5c) compared to APP751sw cells or 






Finally, a measurement of the ADP/ATP ratio revealed lower ADP/ATP ratios 
in both APP transfected cells (Fig. 4.5d) compared to mock cells, indicating that both 
cell lines were functionally producing ATP. APP695sw cells had the lowest 
ADP/ATP ratio, which suggests that most of the ADP in the cell line has been 
converted to ATP in lieu of the high mitochondrial activity. 
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/NADH ratio in cell lines measured using the NAD
+
/NADH assay as described in 
the Materials and Methods section. (b) Mitochondrial membrane potential of the cell lines measured 
using the cationic JC-1 dye. (c) Cytochrome c oxidase (COXIV) activity measured in isolated 
mitochondria from the cell lines. 20µg of mitochondrial protein was used for each assay. (d) 
Intracellular ADP/ATP ratio in cell lines measured using the ADP/ATP assay as described in the 
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Materials and Methods section. For all the assays, each value represents the mean ± SEM of duplicate 
assays for individual samples (n = 3 each).  APP695sw cells displayed significantly higher 
NAD
+
/NADH ratio, mitochondrial membrane potential and COXIV activity compared to APP751sw 
cells (*p<0.05, *p<0.1 and *p<0.01 respectively using Student’s t-test) and mock cells (*p<0.05, 
*p<0.05 and **p<0.01 respectively using Student’s t-test). In addition, the ADP/ATP ratio was also 
significantly lower in both APP695sw and APP751sw cell lines (***p<0.001 using Student’s t-test).       
 
4.2.5 Elevated expression of key tricarboxylic cycle and oxidative 
phosphorylation enzymes in APP695sw transfected cells 
Since there was a relative increase of mitochondrial activity that was 
pronounced in the APP695sw cell lines, it was of interest to determine if this increase 
could have been a result of an increased expression of key components of the ETC 
and the TCA cycle. As such, a handful of genes were selected for analysis and the 
relative expression level of various target genes was determined using a sensitive real-
time RT-PCR approach. To ensure that the results obtained would provide an accurate 
representation of gene expression changes, probes that bind to the exon junction of 
genes were chosen, which minimized the probability of detecting genomic DNA. 
Subsequently, all the raw data obtained from the APP transfected cell clones were 
normalized against readings from mock cells to generate values for the relative gene 
expression level.  
A general increase in the expression level of most TCA cycle enzymes probed 
was observed in both APP transfected cell lines (Fig. 4.6). This increase was evident 
from comparisons of the expression levels of enzymes such as citrate synthase (Fig. 
4.6a), succinate dehydrogenase (Fig. 4.6b) and COX IV (Fig. 4.6c) among the cell 
lines. Collectively, these enzymes play an important role in the functioning of the 
TCA and ETC in the mitochondria, and changes in their expression levels are likely to 
impact mitochondrial function. Citrate synthase is responsible for the breakdown of 
acetyl-coA and its subsequent entry into the TCA cycle for the production of NADH; 
while both succinate dehydrogenase and COX IV are critical complexes of the ETC in 
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the mitochondria that generate the protonmotive force across the mitochondrial 
membrane for ATP production.    
As expected, a marked increase in the gene expression of citrate synthase, 
succinate dehydrogenase and cytochrome c oxidase (COX IV) in APP695sw cells was 
detected as compared to APP751sw or mock cells. Additionally, APP751sw cells also 
showed a significant upregulation of succinate dehydrogenase expression as compared 
to mock cells, though at a lesser extent than that observed in APP695sw cells.  
In addition, another enzyme, isocitrate dehydrogenase involved in the TCA 
cycle was also upregulated significantly in both APP transfected cells (Fig. 4.6d). 
Isocitrate dehydrogenase is an enzyme involved in the third step of the TCA cycle that 
catalyses the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate, 
carbon dioxide and NADH. A slight difference in isocitrate dehydrogenase expression 
level between APP695sw and mock cells was observed, though no significant 
difference was found when comparing between APP695sw and APP751sw cells for 
relative gene expression of isocitrate dehydrogenase.  
In summary, a consistent upregulation of TCA cycle and oxidative 
phosphorylation gene expression was observed in both APP transfected cells with 
APP695sw cells showing a striking increase in gene expression for these enzymes that 
was significantly higher compared to that in APP751sw or mock cells. 
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Figure 4.6 Increased expression of TCA and oxidative phosphorylation genes in the APP696sw 
cell line.  
 
(a)Relative quantification of citrate synthase expression level (b) Relative quantification of succinate 
dehydrogenase expression level (c) Relative quantification of cytochrome c oxidase expression level (d) 
Relative quantification of isocitrate dehydrogenase expression level in cell lysates using real time RT-
PCR. The expression of each target gene was quantified relative to the endogenous β-actin level for 
each sample. Each value represents the mean ± SEM of duplicate assays for individual samples (n = 3 
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each). Significant differences were observed between APP695sw cells and APP751sw cells in the 
expression level of citrate synthase, succinate dehydrogenase and cytochrome c oxidase genes 
(*p<.0.05, **p<0.01, ***p<0.001 respectively using Student’s t-test). Additionally, the isocitrate 
dehydrogenase expression in both APP-transfected cell lines was also upregulated significantly 
compared to mock cells (*p<0.05, **p<0.01 using Student’s t-test).  The probe ID of the respective 
Taqman® probes used are listed in the Materials and Methods section. 
   
4.2.6 Mitochondrial hyperpolarization is associated with increased oxidative 
stress and predisposition to apoptosis in APP695sw cells 
It was established in section 4.4 that the predominant expression of APP695sw 
in neuronal cell lines appears to increase the mitochondrial activity of cells, thus 
causing mitochondrial hyperpolarization in the process. This phenomenon was not 
observed in APP751sw or mock cells. Since mitochondrial hyperpolarization is 
commonly associated with increased oxidative stress (Brownlee 2001, Lin et al. 2005), 
it is possible that the high mitochondrial membrane potential in APP695sw cells 
would result in increased oxidative stress.  
Therefore, the extent of reactive oxygen species (ROS) production was 
measured, which would serve as an indicator of the level of oxidative stress present in 
the neuronal cell cultures. To detect the amount of ROS produced, a sensitive 
detection agent, the H2DCFDA dye was used, which fluoresces upon removal of 
acetate groups by intracellular esterases and subsequent oxidation. An increase in 
ROS levels in both APP transfected neuronal cells was detected; with APP695sw 
producing a significantly larger amount of ROS as compared to mock or APP751sw 
cells (Fig. 4.7a). Further, a marked difference in ROS production was also detected 
between APP695sw and APP751sw cells (p ~ 0.05).  
Since high ROS is associated with apoptosis in cultured neurons (Russell et al. 
2002), it is likely that markers of apoptosis might be present in the cell lines. As 
apoptosis is usually preceded by cytochrome c release into the cytosol and subsequent 
caspase 3 activation, the presence of cytochrome c in cytosolic fractions of the cell 
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lines was determined. Interestingly, there was a significant accumulation of 
cytochrome c in the cytosolic fraction of APP695sw cells in contrast to the low levels 
present in APP751sw or mock cells (Fig. 4.7b). 
 
Figure 4.7 Increased mitochondrial membrane potential in APP695sw cells predisposes cells to 
apoptosis.  
 
(a) Quantification of ROS levels using the H2DCFDA assay as described in the Materials and methods 
section. (b) Immunoblotting analysis of cytochrome c levels in cytosolic fractions. For each sample, 20 
µg of protein was loaded per lane. (c) Caspase-3 activity levels in the respective cell lines measured 
using the Caspase-Glo™ 3/7 assay as described in the materials and methods section. For all the assays, 
each value represents the mean ± SEM of duplicate assays for individual samples normalised with 
respect to mock cells and expressed in terms of percentages (n = 3 each). APP695sw and APP751sw 
cells produced significantly higher ROS than mock cells (***p<0.001 using Student’s t-test). There was 
also a significantly higher amount of ROS in APP695sw cells than APP751sw cells (*p<0.05 using 
Student’s t-test).  Comparing the caspase-3 activity levels among the cell lines, APP695sw cells were 
observed to possess significantly higher caspase-3 activity than APP751sw or mock cells (***p<0.001 
using Student’s t-test). 
              
Because cytochrome c release is known to trigger caspase 3 activation in cell 
death signaling, a caspase-3 activity assay was performed on the neuronal cell lines to 
evaluate the cellular caspase-3 activity among the cell lines. A corresponding increase 
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in caspase-3 activity was found in APP695sw cells that was significantly higher 
compared to APP751sw cells or mock cells that had equal amounts of caspase-3 
activity (Fig. 4.7c). Therefore, it appears that the high oxidative stress in APP695sw 
cells predisposes these cells to apoptosis compared to APP751sw cells. 
 
4.3 Discussion 
To my knowledge, this is the first study that demonstrates a differential ability 
of APP isoforms in regulating glucose metabolism in neuronal cells. Here, a novel 
mechanism in which APP alters glucose metabolism and mitochondrial function is 
presented, which seems to be dependent on the type of APP isoform present. 
To date, APP has been linked to mitochondrial dysfunction via its potential to 
traffic to the organelle when overexpressed (Anandatheerthavarada et al. 2003). 
Additionally, the protein has also been shown to affect mitochondrial dynamics by 
regulating the expression of mitochondrial fission and fusion proteins (Wang et al. 
2008). These numerous findings highlight a plausible association between APP and 
energy homeostasis, specifically in terms of the potential of APP in causing 
mitochondrial dysfunction. However, these studies were mostly performed in cell 
lines that express endogenous APP. With these novel stable cell lines that express only 
a single APP isoform, it would thus be possible to investigate the probable 
ramifications of different APP isoforms on glucose metabolism and mitochondrial 
function without interference from endogenous sources of APP.   
Recently, a handful of studies have established the role of APP in transcription 
and gene expression through production of the APP intracellular domain (AICD) 
(Belyaev et al. 2010, Muller et al. 2008), which is generated via cleavage of the C-
terminal membrane bound fragment by γ-secretase. In this present study, an increase 
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in gene expression of TCA and oxidative phosphorylation enzymes was observed in 
APP-transfected cell clones. However, there was a difference in the extent of gene 
upregulation between the APP695sw and APP751sw cell lines, indicating a 
differential effect that both APP isoforms potentially exert on transcription. In 
particular, a consistent increase in the gene expression of various enzymes was 
detected in APP695sw cell clones, which might be associated with the possibly higher 
amount of AICD produced by the cell line.  
The results from the previous chapter suggest that the APP695sw cell line is 
producing more AICD than the APP751sw cell line. This was evident from the higher 
amount of Aβ produced along with the possibility of an increased γ-secretase activity 
of the APP695sw cells, which is in line with a recent finding that reported a marked 
production of AICD from the amyloidogenic pathway in APP695 transfected neuronal 
cells (Belyaev et al. 2010). Therefore, APP695sw cells might potentially demonstrate 
an increased propensity to regulate gene expression through increased production of 
AICD. Although the full spectrum of gene targets regulated by AICD is still not 
entirely understood, it is possible that APP695sw cells in contrast to APP751sw cells 
might modulate gene expression through an AICD-dependent mechanism due to the 
high levels of AICD that can potentially translocate to the nucleus and initiate gene 
transcription. It is likely that this process is partially responsible for the major increase 
of TCA and oxidative phosphorylation enzyme expression in APP695sw cells as 
reported.                
An association between the increase in gene expression and the increase of 
mitochondrial activity in APP695sw cells was also found, indicating that the high 
mitochondrial activity was probably due to the increase in the expression of TCA and 
oxidative phosphorylation genes in the cell line. Additionally, in both APP transfected 
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cell lines, the mitochondrial function of the cells was either preserved (in the case of 
APP751sw) or increased (in the case of APP695sw). This was in contrast to the 
previously reported disruption of mitochondrial function by the mitochondrial 
localization of APP (Anandatheerthavarada et al. 2003). However, APP was found to 
target to the mitochondria only when it was overexpressed in massive quantities. 
Specifically, the authors only found a predominant localization of APP to the 
mitochondria after performing a transient transfection for 96 hours. As such, it is 
possible that in the current cellular models used, the levels of APP expression had not 
reached a threshold level that would otherwise cause the protein to localize to the 
mitochondria, resulting in mitochondrial dysfunction. It was also observed that the 
increase in mitochondrial activity in the APP695sw cell line was coupled with 
increased glycolysis, suggesting an overall increase in glucose metabolism in the cell 
line. 
Further, the increase in mitochondrial activity in the APP695sw cell lines was 
coupled with an elevation of the mitochondrial membrane potential, indicative of 
mitochondrial hyperpolarization. Since increased mitochondrial membrane potential is 
commonly associated with high ROS levels (Huttemann et al. 2008), the amount of 
ROS production in the cell lines was also evaluated. Expectedly, a major increase in 
ROS production in APP695sw cells as compared to APP751sw cells was observed, 
suggesting an increased oxidative stress inherent in APP695sw cells that is associated 
with the elevated mitochondrial membrane potential in the cell line. Applying these 
results to the context of AD in which there is pronounced oxidative stress in the brain 
(McGrath et al. 2001, Perry et al. 2002), the underlying notion is that increased 
expression of APP751 might be beneficial since there is an overall reduction in ROS 
production and normal functioning of mitochondria when APP751sw is expressed 
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predominantly in neuronal cells. This could also explain why increased levels of the 
KPI-positive APP751 isoform is detected after oxidative stress (Belyaev et al. 2010).  
Interestingly, increased ROS production during hyperglycemia has also been 
associated with a change of mitochondria morphology (Yu et al. 2006). As APP695sw 
overexpression in other cell lines has also been linked to changes in mitochondria 
dynamics that alter the morphology of mitochondria in the process (Wang et al. 2008), 
it is possible that in our APP695sw cell lines, the increased ROS production might 
also be associated with alterations in mitochondria morphology.   
Additionally, the increased mitochondrial membrane potential in APP695sw 
cells seems to sensitize them to apoptosis, possibly through the generation of 
excessive ROS, as indicated by an increase in the basal levels of cytosolic cytochrome 
c and caspase-3 activity. This was in agreement with previous studies on neuronal 
cells that associated mitochondrial hyperpolarization (Iijima et al. 2003), and 
increased ROS with apoptosis (Simon et al. 2000, Johnson et al. 1996). 
In this study, a marked elevation of glucose content in APP695sw cells 
compared to APP751sw or mock cells was also observed. This increase in glucose 
content was accompanied by a corresponding increase in GLUT-3 protein expression 
in APP695sw cells. Therefore, it is likely that this increased synthesis of GLUT-3 
might facilitate a higher intake of glucose into the cell, thus contributing to the high 
intracellular glucose content as observed.  
Further, I also examined if the differential amount of Aβ generated by both 
isoforms could have contributed to the variation in intracellular glucose concentration 
observed. Specifically, Aβ42 was shown to induce glucose uptake in cultured neurons 
instead (Soucek et al. 2003). However, there was no significant fold-change in the 
intracellular glucose content of mock cells that had been incubated with conditioned 
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media from both APP-transfected neuronal cell lines that contains Aβ secreted by the 
cell lines. It is likely that the levels of Aβ generated by both APP-transfected neuronal 
cell lines are not high enough to promote an increase in glucose uptake as reported 
previously. Additionally, this observation also suggests that in both APP-transfected 
cell lines, the increase in free glucose content is largely mediated by the presence of 
APP, thus revealing a novel role of the protein in neuronal glucose regulation.     
In conclusion, the expression of different APP isoforms was found to affect 
mitochondrial activity through differential regulation of gene expression, possibly 
through the ability of the isoforms to generate different amounts of AICD. The 
resulting consequence was an increased expression of major oxidative 
phosphorylation genes that was accompanied by an elevated mitochondrial activity 
and mitochondrial hyperpolarization in APP695sw cells. This was in direct contrast to 
APP751sw cells which maintained the expression of TCA and oxidative 
phosphorylation genes and mitochondrial activity at a level that was on par with that 
of mock cells. Further, since there is also lower ROS produced in the APP751sw cells, 
the implications are that contrary to popular belief, an increased expression of the 
KPI-positive APP751 isoform might be beneficial in AD.                                    
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5. APP isoforms alter insulin signaling differentially in neuronal cells 
5.1 Introduction 
APP has been associated with the development of insulin resistance in a 
cellular model of obesity (Lee et al. 2008). Interestingly in AD, there is also prevalent 
insulin resistance that is accompanied by an upregulation of the KPI-positive APP751 
isoform in the brain. This alteration in APP expression translates into two significant 
populations of APP isoforms that are present in the AD brain, the KPI-positive 
APP751 and the KPI-negative APP695 that is predominantly expressed in neurons. As 
such, it is possible that APP plays a role in regulating insulin signaling in neuronal 
cells and that different isoforms of APP modulate insulin signaling differentially.     
Moreover, since insulin plays a major role in energy homeostasis through its 
various downstream signaling effectors (Wolkow et al. 2000, Rulifson et al. 2002), 
alterations in insulin signaling may result in defective energy metabolism that is 
commonly observed in the AD brain. Thus deciphering the mechanisms in which 
insulin signaling is affected by APP might provide a better understanding on how APP 
regulates metabolism in the brain.     
   
5.2 Results    
5.2.1 Neuronal cells expressing distinct APP isoforms secrete and produce 
differential amounts of insulin 
The source of insulin in the brain used to be regarded as a controversial topic as 
neurons were generally conceived to be incapable of synthesizing insulin. However, it 
was subsequently established that insulin mRNA could be detected in isolated 
neuronal cultures, with the majority of the synthesized insulin being secreted into the 
culture media (Devaskar et al. 1994). As such, it is crucial to determine if the neuronal 
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cell lines that are being used could also produce and secrete insulin. Using a sensitive 
insulin ELISA kit, insulin was detected in both the intracellular cell lysates and 
extracellular culture media thus verifying the previous observations of insulin in 
neurons.  
There was slightly less insulin detected in the culture media of both APP-
transfected cell lines (Fig. 5.1a) as compared to mock cells. However, no difference in 
secreted insulin was found when comparing between both APP-transfected cell lines. 
To ensure that traces of insulin present in the culture media were not included in the 
measurements, fresh culture media that had been incubated in the same conditions and 
duration of time as the cell lines prior to the assay was used as a blank.  
Conversely, a significant difference was found in the amount of intracellular 
insulin between both APP-transfected cell lines and mock cells, with both cell types 
showing an increased amount of intracellular insulin (Fig. 5.1b) relative to that 
observed in mock cells. In addition, the APP695sw cell line was also found to contain 
a significantly larger amount of insulin (p <0.05) as compared to the APP751sw cell 
line. 
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Figure 5.1 Increased intracellular insulin in both APP transfected cell lines.  
 
(a)Quantification of secreted insulin in conditioned culture media from the cell lines. (b) Quantification 
of the intracellular insulin content in all 3 cell lines. Measurements were made using a sensitive insulin 
ELISA test kit as detailed in the Materials and Methods section. Each value represents the mean ± SEM 
of duplicate assays for individual samples (n = 3 each). Significant differences in the intracellular 
insulin content was detected between both APP transfected cell lines and mock cells (**p<0.01, 
***p<0.001 using Student’s t-test). Additionally APP695sw cells also had a higher insulin content 
compared to APP751sw cells (*p<0.05 using Student’s t-test).      
 
5.2.2 Insulin signaling profile of APP transfected cell lines 
Other than examining ways in which insulin production and secretion could 
have been affected by APP isoforms, it was also of interest to determine if the 
expression profile of key players involved in insulin signaling could be modulated by 
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the expression of different APP isoforms. In particular, a recent study had reported 
that decreased expression of IRS-1 and -2 was accompanied by increased IGF-1R 
expression in the cortex of AD patients (Moloney et al. 2010), which further 
highlights the significance of investigating changes to the insulin signaling cascade 
that might be mediated by different APP isoforms. 
Through immunoblotting analysis, the expression of key insulin receptor 
molecules such as the insulin receptor beta (IR) subunit and the IGF-1R was 
confirmed in the neuronal cell lines. No change in the expression level of either IR or 
IGF-1R was detected in either the mock or APP-transfected cells (Fig. 5.2a). 
Subsequently, the expression of IRS effector molecules acting downstream of the 
receptors was investigated. Interestingly, the immunoblots revealed a significant 
decrease in IRS-1 and -2 levels in APP695sw cells (Fig. 5.2b). This was in contrast to 
APP751sw cells and mock cells, which had a greater abundance of IRS, although no 
difference in IRS expression could be detected between mock and APP751sw cells. 
 
Figure 5.2 Alterations in insulin signaling cascade components in transfected cell lines.  
 
(a)Immunoblotting of IGF1R and insulin receptor beta in cell lysates. (b) Immunoblotting of IRS-1 and 
IRS-2 in cell lysates. In both cases, 30 µg of protein was loaded per lane and beta actin was included as 
a loading control. 
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5.2.3 Reduced Akt activation in the APP695sw cell line 
The reduced IRS expression in APP695sw cells indicates a preliminary insulin 
resistance present in the cell line. Therefore, further analysis was performed to 
examine if it would translate to a reduction in Akt activation, which occurs 
downstream of IRS activation by insulin. Akt is a serine-threonine kinase whose 
activation is characterized by phosphorylation at certain amino acid residues of the 
protein due to the combined activation of phosphatidylinositol 3- kinase (PI3K) and 
phosphoinositide-dependent protein kinase (PDK). As shown in Fig. 5.3a, the levels 
of Akt were comparable in all 3 cell lines. This suggests that any variation in Akt 
activation detected could not be attributed to alterations in the total protein level but 
rather changes in the phosphorylation status of the protein itself.  
Subsequently, the expression level of the activated forms of Akt, 
phosphorylated at Thr308 (pAkt (thr 308)) and Ser473 (pAkt (ser473)) respectively 
were examined. Phosphorylation of Akt at both sites would activate the protein. 
Consequently, variations in the phosphorylation status of Akt at these sites would also 
result in different degrees of Akt activation. No change in pAkt (thr308) levels was 
found in all the cell lines while a significant reduction in pAkt (ser473) was found in 
APP695sw cell lines as compared to APP751sw cell lines (Fig. 5.3a). Next I verified 
if this decrease in Akt activation could be a result of reduced levels of effectors 
downstream of IRS in the insulin signaling cascade.  
As mentioned, since Akt requires PI3K and activated phosphoinositide-
dependent protein kinase 1 (pPDK1 (ser241)) before it can be fully activated, the 
expression levels of the p85 regulatory subunit of PI3K and pPDK1 (ser241) in the 
cell lines were further investigated. There was no change in the expression level of 
PI3K or pPDK1 (ser241) (Fig. 5.3b) among all 3 cell lines. However the levels of 
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PDK2, which phosphorylates Akt at Ser473 were not investigated, as the identity of 
this kinase has yet to be confirmed. Despite that, the results thus far suggest that the 
changes in Akt activation in APP695sw cells were mostly due to the decrease in IRS 
expression as demonstrated in section 5.2.  
 
Figure 5.3 Expression of APP695sw reduces the extent of Akt activation in vitro.  
 
(a) Immunoblotting of Akt, pAkt (thr 308) and pAkt (ser473) in cell lysates. (b) Immunoblotting of 
PI3K and pPDK1 (ser241) in cell lysates. In both cases, 30 µg of protein was loaded per lane and beta 
actin was included as a loading control. 
 
5.2.4 GLUT-4 synthesis and trafficking is unaffected by the Akt activation 
status 
Several studies have shown that the translocation of GLUT-4, a glucose 
transporter isoform known to be expressed in the hippocampus (Vannucci et al. 1998) 
is mediated by the activation status of Akt (Cong et al. 1997, Ducluzeau et al. 2002). 
As such, it was of interest to determine if the expression level and trafficking of 
GLUT-4 would be affected by the reduced insulin signaling in the APP695sw cell line, 
characterized by its low IRS content and reduced Akt activation. 
Immunoblotting analysis revealed no distinct differences in the band intensity 
of the GLUT-4 protein (Fig. 5.4a), suggesting that the GLUT-4 protein abundance 
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was not affected by the differential activation status of Akt in the cell lines. Following 
that, a flow cytometric analysis of the GLUT-4 expression level on the plasma 
membrane of the cell lines was performed; to determine if there would be a change in 
the surface expression of GLUT-4 that would indicate differences in the extent of 
protein trafficking to the cell surface. Similarly, no alteration in GLUT-4 surface 
expression was detected between all 3 cell lines (Fig. 5.4b).  
 
Figure 5.4 Unaltered intracellular and surface expression of GLUT-4 in all neuronal cell lines.  
 
(a) Immunoblotting of GLUT-4 in cell lysates. 30 µg of protein was loaded per lane and beta actin was 
included as a loading control. (b) Flow cytometric analysis of GLUT-4 surface expression using anti-
GLUT-4 antibody. Each value represents the mean ± SEM of duplicate assays for individual samples (n 
= 3 each). Readings obtained were normalized against the average value of the mock samples, and 
expressed as percentages with respect to mock cells.      
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5.2.5 Activation status of GSK3β in APP transfected cell lines 
In section 5.3, it was established that there was a marked reduction in Akt 
activation in APP695sw cells. Since Akt is a pivotal molecule involved in regulating 
and amplifying various downstream pathways in insulin signaling, an in-depth 
analysis was performed to further verify the activation status of Akt and its relevance 
to energy metabolism. To do so, the phosphorylation status of GSK3β, a 
serine/threonine kinase known to be phosphorylated by Akt was examined. 
As expected, immunoblot analysis revealed a significant decrease in the 
amount of GSK3β phosphorylated at Ser9 (pGSK3β (ser9)) detected in APP695sw 
cells compared to APP751sw cells (Fig. 5.5). Additionally, slightly higher levels of 
pGSK3β (ser9) were also found in mock cells than APP751sw cells. Notably, there 
were no differences in the amount of GSK3β present in all the cell lines. The total 
GSK3β content was probed to ensure that changes in the phosphorylation status of 
GSK3β could not be due to fluctuations in protein level. Because phosphorylation at 
Ser9 is known to exhibit an inhibitory effect on the activity of GSK3β, the marked 
reduction of pGSK3β (ser9) in the APP695sw cell line could potentially translate to an 
increase in GSK3β activation. 
Subsequently, the phosphorylation status of another isoform of GSK3, GSK3α 
was examined. GSK3α shares a high degree of homology as GSK3β (Forde & Dale 
2007) and is known to be phosphorylated at Ser21 (pGSK3α (ser21)) by Akt (Cross et 
al. 1995). In general, a similar trend as per what was reported for pGSK3β (ser9) was 
observed. Again, APP695sw cells were found to contain a lower amount of pGSK3α 
(ser21) than APP751sw or mock cells despite no change in the total GSK3α protein 
content in all 3 cell lines (Fig. 5.5). Since both GSK3α and GSK3β are downstream 
targets of Akt and similar changes in pGSK3α (ser21) and pGSK3β (ser9) levels were 
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observed in the cell lines, the results presented further confirm the decrease in 
pGSK3β (ser9) in APP695sw cells to be a result of reduced Akt activation as 
described earlier. 
 
Figure 5.5 APP695sw causes a decline in GSK3α/β phosphorylation.  
 
Immunoblotting analysis of GSK3α, GSK3β, pGSK3α(Ser21) and pGSK3β(ser9) in cell lysates. 30 µg 
of protein was loaded per lane and beta actin was included as a loading control.  
 
5.3 Discussion 
This study has demonstrated a novel role of APP isoforms in the differential 
regulation of insulin signaling. Specifically expression of the KPI-positive APP751sw 
isoform appears to restore insulin signaling to near normal physiological levels 
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whereas the KPI-negative isoform APP695sw seems to predispose neuronal cells to an 
insulin-resistant phenotype.  
To date, APP has no known function in insulin signaling. However previous 
studies conducted seem to suggest its putative involvement in insulin signaling since 
an increase in APP gene expression and protein synthesis was observed following the 
induction of diabetes in the brain (Lester-Coll et al. 2006, Wallace et al. 1993). In this 
study, it was found that expression of APP695sw causes the downregulation of both 
IRS-1 and IRS-2, a phenomenon that is well documented in AD brains (Steen et al. 
2005, Moloney et al. 2010). This was in stark contrast to APP751sw cells, which 
presented with a profile almost similar to that of mock cells. Because APP751sw 
contains an additional KPI domain which is known to inhibit the action of certain 
serine proteases (Petersen et al. 1994), it is possible that the presence of the KPI 
domain in the protein could have prevented the degradation of IRS proteins. However, 
more studies would have to be performed to elucidate the potential contribution of the 
KPI domain to the maintenance of IRS protein levels.  
Previously, Aβ has been reported to target IRS-1 for degradation via JNK 
activation in cultured cells (Ma et al. 2009). Although it is logical to assume that the 
high levels of extracellular Aβ generated in APP695sw cells could have contributed 
partially to the degradation of IRS-1, the comparable levels of IRS between 
APP751sw cells and mock cells suggest that Aβ probably plays a minor role in 
degradation of IRS-1.  Particularly, a dose dependent decrease of IRS-1 corresponding 
to the amount of Aβ produced by both APP-transfected cell lines should be detected if 
Aβ was a major factor in the degradation of IRS-1 in this system. Hence this further 
reinforces the direct association between the parent APP molecule and its involvement 
in the regulation of intracellular IRS levels. These results also suggest that it is likely 
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that the amount of Aβ generated would need to exceed a certain threshold before 
degradation of IRS proteins takes place. 
Based on the results, a downregulation of IRS-2 in APP695sw compared to 
APP751sw cells was also observed. A previous study conducted on brain specific 
IRS-2 knockout mice had revealed an association between reduced IRS-2 levels and 
hyperinsulinemia (Taguchi et al. 2007). This was consistent with the current results 
obtained that showed a significant upregulation of intracellular insulin in APP695sw 
cells. The pronounced increase in insulin content in APP695sw cells as compared to 
APP751sw cells is likely to be a compensatory response to the decrement of both IRS-
1 and IRS-2 levels, since APP695sw cells displayed a more drastic reduction in IRS 
levels compared to APP751sw cells.  
Additionally, there was also a significantly higher amount of intracellular 
insulin in both APP transfected cell lines as compared to mock cells. This was in 
direct contrast to the low levels of secreted insulin detected in the culture media of 
both transfected cell lines. Thus it is plausible that the insulin secretion mechanism in 
both APP transfected cell lines is compromised. Despite that, the comparable amount 
of secreted insulin by both APP cell lines implies that variations in the insulin content 
in the AD brain are likely to be contributed by other cell types in the brain or even a 
possible consequence of systemic changes. 
Interestingly there was no change in insulin receptor beta or IGF1R levels in 
both APP transfected cells despite another study on AD brains that showed a decline 
in insulin receptor beta expression and an overall increase in IGF1R levels (Moloney 
et al. 2010). As these changes were detected post-mortem, it is likely that aging could 
have contributed to the observed changes. Since it was not possible to examine aging-
related changes in a cell culture system, the only logical conclusion that can be 
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reached is that the presence of either APP isoform has no effect on the overall 
expression of insulin receptor molecules. Additionally, as there was only a specific 
subset of brain cells examined, specifically neuronal cells, it is possible that other cell 
types in the brain might also have contributed to the changes in insulin receptor beta 
or IGF1R seen in AD.  
In evaluating the insulin signaling profile of the cell lines, changes occurring 
downstream of IRS were also investigated, one of which was GLUT-4 synthesis and 
translocation that could have impacted the uptake of glucose into the cells. 
Surprisingly, no difference in GLUT-4 protein expression was found in both the 
intracellular compartment and the cell surface in APP695sw cells as compared to 
APP751sw cells. This occurred despite the significantly low level of IRS and a 
subsequent reduced Akt activation in the APP695sw cells. The above observation was 
unexpected since Akt activation had previously been shown to induce GLUT-4 
translocation. However as the amount of secreted insulin in both APP transfected cell 
lines is similar, it is possible that in neuronal cells, changes in the extracellular insulin 
content would have to occur in combination with a marked increase in intracellular 
insulin resistance to facilitate measurable changes in GLUT-4 translocation. 
Other than examining potential changes in GLUT-4 translocation, another 
important target of insulin signaling, GSK3β was also examined. As mentioned, the 
reduction in pGSK3β (ser9) in APP695sw cells suggests an enhanced GSK3β activity, 
which might lead to mitochondrial dysfunction through different mechanisms. Further, 
GSK3β is also known to phosphorylate tau (Rankin et al. 2007), which suggests that 
the expression of APP751sw in neuronal cells might serve to limit the extent of tau 
phosphorylation indirectly by maintaining the levels of key molecules such as IRS that 
are involved in insulin signaling. 
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The finding of an overall reduction in Akt activation in APP695sw cells and 
the subsequent decrease in pGSK3α (ser21) and pGSK3β (ser9) suggests that the 
decreased Akt activation can potentially affect other downstream targets of Akt other 
than GSK3. Since Akt regulates the activity of a myriad of targets such as 
transcription factors like FoxO and other kinases (Manning & Cantley 2007), it is 
likely that the combinatorial effect of the changes elicited downstream could affect the 
overall metabolic phenotype in the cell. In particular, the transcription factor FoxO has 
been implicated in the regulation of several target genes involved in metabolism 
(Barthel et al. 2005). Since phosphorylation by Akt has been proven to inhibit FoxO 
activity (Brunet et al. 1999) and the Akt activity in APP695sw cells is reduced, it is 
reasonable to infer that the intrinsic FoxO activity would be higher in APP695sw cells 
as compared to APP751sw cells. Thus, an ensuing outcome of an elevated FoxO 
activity caused by changes in insulin signaling might be an alteration in cellular 
metabolism in the APP695sw cell line due to an increased gene expression of certain 
targets.                    
In summary, this study implicates a possible association between APP 
isoforms and insulin signaling in neuronal cells. The results obtained suggest that 
upstream changes in insulin signaling might have resulted in alterations in GSK3 
phosphorylation through the PI3K/Akt pathway, which is likely to affect 
mitochondrial function and tau phosphorylation. This effect was clearly more evident 
in APP695sw cells that displayed a significant downregulation of IRS molecules and 
subsequent decreased PI3K/Akt/GSK signaling than APP751sw cells. Additionally, 
the reduced Akt activation in APP695sw cells also potentially translates to an 
increased FoxO activity, which could result in an alteration of the gene expression 
profile of certain metabolic genes possibly affecting metabolism in the process. Taken 
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together, the results suggest that in AD, upregulation of the KPI-positive APP751 
isoform might serve to return insulin signaling to normal levels, thus restoring energy 
homeostasis in the brain and reducing the extent of tau phosphorylation. Although the 
exact mechanism of action of the KPI domain in this aspect is still unknown, the 
current findings highlight a novel role that APP751 upregulation might play in 
neuronal insulin signaling and subsequent energy metabolism. 
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6. Increasing amyloid burden is associated with declining glucose 
metabolism during aging in APPsw/PS1∆E9 mice 
6.1 Introduction 
Numerous imaging studies have reported a decline of the cerebral metabolic rate 
for glucose (CMRglc) in patients that suffer from MCI or AD and in cases of MCI 
patients that progressed to AD (Mosconi et al. 2006, Drzezga et al. 2003, Mosconi et 
al. 2005). The connection between reductions in CMRglc and cognitive dysfunction 
was further strengthened by a subsequent study in 2008 that identified hippocampal 
hypometabolism as an ideal predictor of cognitive dysfunction (Mosconi et al. 2008). 
Since there is also a significant accumulation of Aβ in MCI and AD, especially during 
the progression from MCI to AD, there might be a correlation between the increasing 
Aβ content in diseased brain and the decreasing CMRglc.  
Additionally, a two year follow-up study on AD patients found that amyloid 
deposition appears to plateau by the early clinical stages of the disease, thus placing 
the occurrence of Aβ deposition before declining CMRglc (Engler et al. 2006). 
However, the extent at which Aβ deposition affects brain glucose metabolism remains 
relatively unknown. Therefore, it was of interest to determine if, and how increasing 
Aβ might cause drastic reductions in glucose metabolism through differential 
regulation of glycolysis and glucose uptake, resulting in elevated brain glucose 
content.  
To address this issue, a transgenic mouse model, the APPsw/PS1∆E9 mouse 
strain was selected for this study. The APPsw/PS1∆E9 mouse strain contains a 
humanized mouse APP transgene together with a human PS1 transgene that causes it 
to produce increasing Aβ with age. Therefore this strain is a suitable candidate for 
studying the effects of an increasing amyloid deposition. The presence of both 
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transgenes in the hemizygous mice was verified through genotyping analysis. In 
particular, female hemizygous APPsw/PS1∆E9 mice were selected for analysis and 
wildtype littermates that did not contain either transgene were used as controls.  
Female mice were chosen for this study as female mice from other similar 
mouse strains such as the APP/PS1 mouse strain or the triple transgenic Alzheimer’s 
disease model mice (3xTg-AD), which contain mutations in both APP and presenilin 
to increase the production of Aβ have been reported to produce a significantly higher 
amyloid burden and subsequent plaque deposition than their male counterparts (Wang 
et al. 2003, Hirata-Fukae et al. 2008). In particular, female APP/PS1 mice carry a 
heavier amyloid burden and plaque deposition that increases with age, especially at 12 
and 17 months of age. Further, since population studies of humans have also identified 
a higher incidence of AD in females compared to males (Vina & Lloret 2010, Vina et 
al. 2007), only female APPsw/PS1∆E9 mice were used for the subsequent studies.  
 
6.2 Results 
6.2.1 The Aβ42 level increases significantly with age in female APPsw/PS1∆E9 
mice 
Aβ levels in the transgenic mouse brains were quantified using a sensitive Aβ 
ELISA test kit after extraction of the peptides from tissue lysates using guanidine 
hydrochloride. As expected, both species of Aβ (Aβ40 and Aβ42) were detected in the 
APPsw/PS1∆E9 mouse brain. Further analysis of the Aβ ELISA results found the 
levels of Aβ40 to be relatively constant throughout aging in these mice (Fig. 6.1a). 
Subsequent analysis using One-way ANOVA also did not reveal any significant 
differences in Aβ40 content that occurred with aging in the APPsw/PS1∆E9 mice. 
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Conversely, Aβ42 levels were observed to increase with aging in the transgenic 
mice. Similar to Aβ40, the data set obtained for the Aβ42 content of the mice at 
different timepoints was subjected to One-way ANOVA analysis, which revealed 
significant differences (p <0.05) between the Aβ42 levels of the mice at different 
timepoints. Further comparisons of the Aβ42 levels of the mice at the various 
timepoints using Student t-tests found that the significant increase in Aβ42 content 
occurred as early as 6 months of age in the mice (Fig. 6.1b), and peaked when the 
mice reached 15 months of age.  
A subsequent comparison between the Aβ40 and Aβ42 content at the selected 
timepoints of study also confirmed a higher level of Aβ42 that was consistently 
observed beginning from 6 months of age in the mice. In particular, there was a 
significant difference in Aβ content at 15 months of age, in which the ratio of Aβ42 to 
Aβ40 was calculated to be approximately 7 times, indicating that levels of Aβ42 far 
exceed that of Aβ40 as aging progressed. 
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Figure 6.1 Aβ42 levels increase with aging in APPsw/PS1∆E9 mice. 
 
(a) Relative quantification of Aβ40 and Aβ42 using ELISA performed on Aβ extracted from mouse 
brain lysates. Each value represents the mean ± SEM of assays for duplicate samples (n = 3 each). 
Significant differences were observed in the Aβ42 and Aβ40 levels at 15 months of age (*p < 0.1 using 
Student’s t-test). (b) Table comparing the difference in Aβ42 content at different timepoints of age 
compared to that at 3 months of age. Significant increases in Aβ42 content was detected between mice 
at 6, 12 and 15 months of age respectively compared to mice at 3 months of age (*p <0.1, **p <0.05 
and ***p <0.01 using Student’s t-test).       
  
6.2.2 Depreciation of brain glucose is associated with increasing amyloid 
deposition in APPsw/PS1∆E9 mice with aging  
An opposing trend in the total brain glucose content was observed when 
comparisons were made between wildtype female mice of the B6C3 strain and 
transgenic APPsw/PS1∆E9 mice (Fig. 6.2). Wildtype mice of the same gender were 
included in subsequent studies as a control. In wildtype mice, the brain glucose 
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content was found to increase gradually with aging, suggesting reductions in CMRglc 
with time that resulted in an overall increase in the absolute glucose content. Similar 
observations were reported in imaging studies on healthy humans as they aged, with 
reductions in the relative metabolic rate of glucose in certain regions of the brain for 
both gender (Fujimoto et al. 2008).     
In contrast, the total brain glucose in APPsw/PS1∆E9 mice was noted to 
depreciate rapidly with aging. In addition, a significant reduction in the total brain 
glucose content was detected at 12 and 15 months of age in the female transgenic 
mice as compared to wildtype mice. This marked difference in glucose content, which 
was especially pronounced at 15 months of age coincided with a significantly heavy 
amyloid burden in the mice.   
Interestingly, a slight increase in total glucose was observed at the earlier time 
points of 3 and 6 months in the APPsw/PS1∆E9 mice compared to wildtype mice, 
suggesting early manifestations of CMRglc reduction that occurred as amyloid 
deposition first began. However, further studies investigating factors affecting glucose 
uptake and the metabolic breakdown of glucose are required before the observed 
changes in brain glucose in the APPsw/PS1∆E9 mice can be accounted for. 
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Figure 6.2 The brain glucose concentration of APPsw/PS1∆E9 mice depreciates as its amyloid 
content increases with aging.  
 
Quantification of brain glucose content using a sensitive amplex red glucose kit as detailed in the 
“Materials and methods” section. Values obtained were normalized against the wet weight of the brain 
tissue and expressed in terms of µM of glucose per mg of wet brain mass. Each value represents the 
mean ± SEM of duplicate assays for individual samples (n = 4 each). At 12 and 15 months of age, the 
brain glucose in wildtype mice was significantly higher than that of APPsw/PS1∆E9 mice at 2.15 and 
2.67 fold respectively (* p<0.05 and **p<0.01 using Student’s t-test). APPsw/PS1∆E9 mice are 
denoted as APP/PSEN in the above figure. 
 
6.2.3 Downregulated expression of GLUT-3 and -4 is associated with increasing 
amyloid deposition in APPsw/PS1∆E9 mice 
Next, the expression profile of major GLUT molecules that might affect the 
extent of glucose uptake into the brain was examined. As mentioned previously, two 
GLUT molecules, namely GLUT-3 and GLUT-4 that have been implicated in brain 
glucose transport were chosen for this study. A consistent and gradual increase in the 
expression of both GLUT molecules was observed with aging in both wildtype and 
APPsw/PS1∆E9 mice (Fig. 6.3a and b). 
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A comparison of the western blot band intensity between the two different 
mouse strains using densitometry revealed a significant decrease in GLUT-4 
expression at 12 and 15 months of age in APPsw/PS1∆E9 mice when compared with 
wildtype mice (Fig. 6.3b). This corresponded with the marked increase in Aβ 
accumulation that occurred in the transgenic mice. Further, there was also consistently 
less GLUT-4 in APPsw/PS1∆E9 mice compared to wildtype mice at all timepoints. A 
slight decrease in GLUT-3 was also observed at 15 months of age in the 
APPsw/PS1∆E9 mice as compared to wildtype mice. The results suggest that as 
amyloid deposition reaches a significantly high amount, the expression of key glucose 
transporters such as GLUT-4 is downregulated, which might have implications on 
glucose uptake in the brain.    
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Figure 6.3 Differential expression profile of GLUT molecules with aging in both wildtype and 
APPsw/PS1∆E9 mice.  
 
(a)Immunoblotting analysis of GLUT-3 and -4 in brain tissue lysates. 30 µg of protein was loaded per 
lane and beta actin was included as a loading control. (b) Densitometry analysis of GLUT-4 expression 
respectively. Analysis was performed using Image J software and values obtained for each sample were 
normalised against the beta actin values for individual samples. A significant decrease in GLUT-4 
expression was detected in APPsw/PS1∆E9 mice at 12 and 15 months of age compared to wildtype 
mice (*p<0.1 and **p<0.05 using Student’s t-test). APPsw/PS1∆E9 mice are denoted as APP/PSEN in 
the above figure.     
 
6.2.4 Levels of brain insulin decrease rapidly with aging and increased amyloid 
deposition in APPsw/PS1∆E9 mice 
Besides GLUTs which control glucose uptake directly into cells, insulin is 
another crucial factor that can potentially regulate the uptake of glucose by binding to 
insulin receptors, thereby facilitating the subsequent activation of downstream 
signaling cascades to bring about glucose uptake. It is known to diffuse into the brain 
by crossing the blood brain barrier. As such, fluctuations in insulin levels in the brain 
might be critical towards the maintenance of the total glucose content. Therefore, the 
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total insulin levels in the mouse brain lysates were examined using a sensitive insulin 
ELISA test kit. 
 
Figure 6.4 Brain insulin levels are consistently low in APPsw/PS1∆E9 mice and decrease rapidly 
with aging.   
 
Insulin levels in brain tissue lysates were probed using an insulin ELISA test kit. Values obtained were 
normalized against the wet weight of the brain tissue and expressed in terms of ng of insulin per gram 
of wet brain mass. Each value represents the mean ± SEM of duplicate assays for individual samples (n 
= 4 each). A significant difference in insulin content was detected at 12 and 15 months of age between 
wildtype and APPsw/PS1∆E9 mice (**p <0.01, ***p <0.001 using Student’s t-test). The calculated 
fold change between the insulin content of wildtype and APPsw/PS1∆E9 mice was 6.8 and 4.3 fold 
respectively. APPsw/PS1∆E9 mice are denoted as APP/PSEN in the above figure. 
 
Insulin levels in wildtype mice were noted to mirror that of the glucose 
concentration curve for wildtype mice as shown in figure 6.2. Briefly, brain insulin 
levels increased gradually with aging, peaking at 12 months of age (Fig. 6.4). On the 
other hand, APPsw/PS1∆E9 mice presented with low brain insulin levels throughout 
aging. In particular, the insulin content decreased drastically after the mice reached 6 
months of age, which coincided with the timepoint at which Aβ concentrations began 
to increase (Fig 6.4). Significant differences in brain insulin were also observed at 12 
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and 15 months of age when comparing between wildtype and APPsw/PS1∆E9 mice. 
Specifically, huge fold-changes of 6.8 and 4.3 were calculated between the brain 
insulin content of wildtype and APPsw/PS1∆E9 mice at 12 and 15 months of age 
respectively. Taken together, the results obtained hint at an association between 
increasing Aβ production and decreasing insulin content. 
 
6.2.5 Insulin receptor expression increases with Aβ generation in 
APPsw/PS1∆E9 mice 
Since increasing Aβ production potentially causes a decline in the brain insulin 
content, it was of interest to determine if insulin receptor expression would also be 
altered due to the low insulin levels and elevated production of Aβ in the 
APPsw/PS1∆E9 mice. Changes in the expression level of insulin receptors can 
potentially affect the extent of insulin signaling activation, as insulin receptors are 
required for the activation of insulin signaling by insulin binding. Therefore, an 
immunoblotting analysis of insulin receptor expression was performed to elucidate 
possible differences in insulin receptor expression (Fig. 6.5a).   
Subsequently, the immunoblots obtained were analysed by densitometry. For 
both wildtype and APPsw/PS1∆E9 mice, a gradual increase in IR expression was 
detected during aging. Further, a slight increase in insulin receptor beta (IR) 
expression was also detected in the APPsw/PS1∆E9 mice compared to wildtype 
mice in most of the timepoints analysed (Fig. 6.5b).    
Interestingly, a marked increase in the expression of insulin-like growth factor 
1 receptor (IGF-1R) was detected in APPsw/PS1∆E9 mice with aging. This was in 
contrast to the IGF-1R expression in wildtype mice, which remained relatively 
constant with aging (Fig. 6.5c). A further comparison between the expression of IGF-
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1R in wildtype and APPsw/PS1∆E9 at 12 and 15 months of age also revealed a 
significantly large increase in IGF-1R expression in APPsw/PS1∆E9 mice compared 
to wildtype mice, which coincided with high Aβ levels. The results obtained thus far 
appear to suggest a general increase in insulin receptor expression that occurs with Aβ 
deposition in APPsw/PS1∆E9 mice. 
     
 
 
 100 | P a g e  
 
 
Figure 6.5. Insulin receptor expression profile of wildtype and APPsw/PS1∆E9 mice.  
 
(a)Immunoblotting analysis of IGF-1R and insulin receptor beta (IR) in brain tissue lysates, 
representative of two runs. 30 µg of protein was loaded per lane and beta actin was included as a 
loading control. (b) Densitometry analysis of IR and (c) Densitometry analysis of IGF-1R. Analysis 
was performed using Image J software and values obtained for each sample were normalised against 
the beta actin values for individual samples. A significant increase in IR expression was detected in 
APPsw/PS1∆E9 mice at 3, 6 and 15 months of age compared to wildtype mice (*p<0.05 and **p<0.01 
using Student’s t-test).  Additionally, a significant increase in IGF-1R expression was also detected in 
APPsw/PS1∆E9 mice at 12 and 15 months of age compared to wildtype mice (***p<0.001 using 
Student’s t-test). APPsw/PS1∆E9 mice are denoted as APP/PSEN in the above figure.    
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6.2.6 Increased expression of insulin receptor substrate molecules with 
increasing Aβ generation in APPsw/PS1∆E9 mice 
Following the detected changes in insulin levels and the expression profile of 
key insulin receptors in APPsw/PS1∆E9 mice, the effect of an increasing Aβ amount 
on insulin receptor substrate (IRS) molecules was examined. As mentioned previously, 
IRS molecules play a crucial role in insulin signaling as they act as docking proteins 
in the amplification of insulin signaling initiated by insulin receptor activation. 
Therefore, further immunoblotting analysis was performed on the mouse brain lysates 
(Fig. 6.6a). 
To ensure a fair comparison among samples, densitometry calculations were 
made using β-actin as an endogenous control (Fig. 6.6b and 6.6c). It was found that 
the levels of both IRS-1 and -2 did not change as the wildtype mice aged. However in 
the APPsw/PS1∆E9 mice, there was an increased expression of IRS-1 and -2 with 
aging. Additionally, the expression of IRS-1 and -2 was also much higher in the 
APPsw/PS1∆E9 mice as compared to wildtype mice at 12 and 15 months of age 
respectively that corresponded with a significant increase in Aβ production. There was 
also a higher amount of IRS-1 present as compared to IRS-2 in the APPsw/PS1∆E9 
mice at the later timepoints. 
 
 




Figure 6.6 Increased IRS-1 and IRS-2 expression at 12 and 15 months of age in APPsw/PS1∆E9 
mice. 
 
(a)Immunoblotting analysis of IRS-1 and IRS-2 in brain tissue lysates, representative of two runs. 50 
µg of protein was loaded per lane and beta actin was included as a loading control. (b) and (c) 
Densitometry analysis of IRS-1 and IRS-2 expression respectively. Analysis was performed using 
Image J software and values obtained for each sample were normalised against the beta actin values for 
individual samples. A significant increase in both IRS-1 and IRS-2 expression was detected in 
APPsw/PS1∆E9 mice at 12 and 15 months of age compared to wildtype mice (*p<0.05 and **p<0.01 
using Student’s t-test). APPsw/PS1∆E9 mice are denoted as APP/PSEN in the above figure.   
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6.2.7 Decreased Akt activation in APPsw/PS1∆E9 mice 
The changes in the expression profile of insulin receptors and signaling 
molecules such as IRS in the APPsw/PS1∆E9 mice prompted me to examine the 
implications of such alterations upstream in the insulin signaling cascade on 
downstream players like Akt that play a pivotal role in various intracellular signaling 
pathways such as glucose uptake, GSK-3β activation among others. 
Immunoblotting blotting analysis was performed and it was observed that the 
levels of Akt remained fairly constant throughout aging for both wildtype and 
APPsw/PS1∆E9 mice (Fig. 6.7a). However, differences in the band intensity of pAkt 
(ser473) suggested that changes in the phosphorylation status of Akt were detected as 
early as 3 months of age in the APPsw/PS1∆E9 mice as compared to wildtype mice. 
Additionally through densitometry analysis, it was also found that the amount of pAkt 
(ser473) detected at 12 and 15 months of age in the APPsw/PS1∆E9 mice also 
decreased slightly as compared to that at 3 months of age, implying that as the 
production of Aβ increased with aging, slight decrements in the pAkt (ser473) levels 
occurred (Fig. 6.7b).  
As mentioned previously, the phosphorylation of Akt at the serine 473 residue is 
essential in the complete activation of Akt. Thus, any variation in pAkt (ser473) levels 
would affect the activity of Akt and subsequent signaling pathways. In this case, the 
decrease in pAkt (ser473) with aging and Aβ deposition in the APPsw/PS1∆E9 mice 
also suggests a decreased Akt activity in the mice. 




Figure 6.7 Akt expression profile of wildtype and APPsw/PS1∆E9 mice at various timepoints.   
 
(a)Immunoblotting analysis of Akt and pAkt (ser473) in brain tissue lysates, representative of two runs. 
50 µg of protein was loaded per lane and beta actin was included as a loading control. (b) Densitometry 
analysis of pAkt (ser473) levels in APPsw/PS1∆E9 mice across different timepoints. Analysis was 
performed using Image J software and values obtained for each sample were normalised against the 
beta actin values for individual samples. A significant decrease in both pAkt (ser473) expression was 
detected in APPsw/PS1∆E9 mice at 12 and 15 months of age compared to wildtype mice (*p<0.05 and 
**p<0.01 using Student’s t-test). APPsw/PS1∆E9 mice are denoted as APP/PSEN in the above figure. 
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6.2.8 Decreased glycolysis occurs early during aging in APPsw/PS1∆E9 mice 
and is accompanied by a downregulation in mitochondrial complex I 
expression 
The earlier sections described in this chapter demonstrated an association 
between Aβ production and factors affecting glucose uptake. Subsequently, the 
possible implication of an increasing Aβ amount on the breakdown of glucose was 
examined. Therefore, pyruvate levels in the brain tissues were measured, and the trend 
obtained for the brain pyruvate content was studied together with that of the brain 
glucose content. Comparing the data obtained from APPsw/PS1∆E9 mice to wildtype 
mice, it was observed that the slight increase in brain glucose that occurred between 3 
to 6 months (Fig. 6.2) was associated with a reduction in pyruvate levels in 
APPsw/PS1∆E9 mice (Fig. 6.8a), suggestive of a decline in glycolysis in the 
APPsw/PS1∆E9 mice.  
Further, the brain pyruvate content in the APPsw/PS1∆E9 mice continued to 
decrease with aging and was observed to drop rapidly as the mice aged after 6 months 
of age. Thus, it is likely that the decline in glycolysis persists throughout aging in the 
APPsw/PS1∆E9 mice. Conversely, the pyruvate levels in the wildtype mice remained 
relatively stable throughout the different timepoints. Differences in pyruvate content 
between wildtype and APPsw/PS1∆E9 mice were most pronounced at 12 and 15 
months of age, in which the pyruvate content of the APPsw/PS1∆E9 mice was much 
lower. The calculated fold change in the pyruvate content of wildtype mice was found 
to be 5.07 and 6.27 fold higher than that of APPsw/PS1∆E9 mice.  
Subsequently, the expression profile of markers for certain mitochondrial 
complex proteins was probed, and a consistent downregulation of a mitochondrial 
complex I protein, NADH dehydrogenase flavoprotein 2 (NDUFV2) was detected in 
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the brains of APPsw/PS1∆E9 mice that began as early as 3 months of age. On the 
other hand, there was no noticeable change in the expression of cytochrome c oxidase 
(COXIV), a mitochondrial complex IV protein in both wildtype and APPsw/PS1∆E9 
mice (Fig. 6.8b). Generally, the protein levels of both mitochondrial complex proteins 
remained unchanged throughout aging in both strains of mice, suggesting that the 
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Figure 6.8 Declining brain pyruvate in APPsw/PS1∆E9 mice is accompanied by low expression of 
mitochondrial complex I protein. 
 
(a)Quantification of brain pyruvate content in mouse brain lysates. Values obtained were normalized 
against the wet weight of the brain tissue and expressed in terms of µM of pyruvate per mg of wet brain 
mass. Each value represents the mean ± SEM of duplicate assays for individual samples (n = 4 each). 
At 12 and 15 months of age, the pyruvate levels in wildtype mice was significantly higher than that of 
APPsw/PS1∆E9 mice at  5.07 and  6.27 fold respectively (** p<0.01 and ***p<0.001 using Student’s t-
test). (b) Immunoblotting analysis of mitochondrial complex I and IV proteins in total brain tissue 
lysates, representative of two runs. 50 µg of protein was loaded per lane and beta actin was included as 
a loading control. APPsw/PS1∆E9 mice are denoted as APP/PSEN in the above figure. 
 
6.3 Discussion 
The preliminary findings from this study have strengthened the plausible 
association between Aβ and the regulation of glucose metabolism, which has been a 
controversial subject for discussion as several brain imaging studies have yielded 
conflicting results. As such, the association between Aβ and glucose hypometabolism 
in the Alzheimer’s diseases brain remains unclear. In this study, emphasis was placed 
on the pathways leading to glucose uptake and breakdown in order to assess the 
impact of Aβ on various aspects of glucose metabolism. Generally, the total brain 
glucose content was observed to decrease with an increasing production of Aβ, 
suggesting defective uptake of glucose that occurs with a high Aβ load. 
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For this study, the APPsw/PS1∆E9 mouse strain was chosen as these 
transgenic mice are engineered to produce increasing Aβ with aging, which makes 
them suitable candidates for investigating the effect associated with an elevated 
production of Aβ. In particular, the amount of Aβ42 produced showed a marked 
increase with aging in these mice, while the levels of Aβ40 remained constant. This 
observation was largely in agreement with other studies using the same strain of mice 
(Jankowsky et al. 2004). Additionally, the significantly high amount of Aβ42 
generated with age is likely to result in a heavy amyloid plaque load, since Aβ42 is 
known to be highly amyloidogenic with an increased likelihood of aggregation than 
Aβ40. Subsequent histological analysis of the APPsw/PS1∆E9 mouse brain by 
Jankowsky and colleagues (Jankowsky et al, 2004) also revealed a significant number 
of plaques evident by 12 months of age in these mice, which corresponded to the high 
amount of Aβ42 produced in these mice. As such, judging from the high levels of 
Aβ42 detected, it is likely that there is also a high plaque load in the female 
APPsw/PS1∆E9 mice used for this study. 
The trend observed for the total brain glucose content in the APPsw/PS1∆E9 
mice suggests a differential effect that Aβ exerts on glucose metabolism at different 
concentrations. Interestingly at lower concentrations, Aβ, in particular Aβ42 appears 
to affect the breakdown of glucose to pyruvate, thus resulting in a high glucose 
content that was coupled with low pyruvate levels when comparing between 
transgenic and wildtype mice that were between 3 to 6 months in age. This 
observation deviated slightly from a previous study that showed Aβ deposition to 
precede a decline in the metabolic rate of glucose (Engler et al, 2006). Instead, a close 
correlation was observed between increasing Aβ42 levels and impaired glycolysis, 
which resulted in a high brain glucose level. The high glucose levels detected are 
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unlikely to be caused by an increased glucose uptake, since no increase in glucose 
transporter expression or insulin receptor levels or signaling components were found, 
which implies that the high brain glucose and low pyruvate content was likely caused 
by a decline in the metabolic rate of glucose. It is possible that Aβ exerts an inhibitory 
effect on enzymatic activities responsible for the breakdown of glucose to pyruvate. 
However, to date, the effect of Aβ on glycolytic enzymatic activity has not been 
extensively characterized. As such more studies would need to be done before the 
exact pathway that is affected can be identified. 
As the amount of Aβ increased exponentially, which might be indicative of a 
late AD setting, a marked decrease in the amount of brain glucose was detected 
instead. This was unexpected since I anticipated the decline in the cerebral metabolic 
rate of glucose (CMRglc) (indicated by the high glucose and low pyruvate levels) to 
persist and worsen with increasing Aβ concentrations, which would likely result in a 
higher amount of brain glucose measured in the APPsw/PS1∆E9 mice at later 
timepoints as compared to the wildtype mice. Therefore, the results suggest a primary 
defect in glucose uptake that probably worsened with increasing Aβ production. As 
such, even if the low CMRglc continued with aging in the APPsw/PS1∆E9 mice, the 
effects caused by such a phenomenon would be less pronounced in the face of an 
impaired glucose uptake, which would lower the total brain glucose content 
significantly. 
Two other potential factors that could affect brain glucose uptake in the mice, 
namely the expression profile of GLUT molecules and that of insulin signaling 
components were also examined. Both were found to be affected drastically by the 
marked production of Aβ in the later timepoints of 12 and 15 months. The finding of a 
decreased GLUT-3 expression has been reported previously in other studies on AD 
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brains (Simpson et al. 1994). Similarly, there was a reduction in the amount of GLUT-
3 and -4 molecules in APPsw/PS1∆E9 mice at 12 and 15 months of age, which 
coincided with a high amyloid load in the mice. These results imply that the presence 
of Aβ alone can potentially decrease the expression of GLUT molecules. However, it 
appears that the expression of GLUT molecules is only affected when the Aβ 
concentration reaches a certain threshold, since there was no difference in the amount 
of GLUT molecules detected in the earlier timepoints of 3 and 6 months when 
comparing between transgenic and wildtype mice. Further, since GLUT-4 was found 
to be localized on the blood brain barrier (Ngarmukos et al. 2001), alterations in its 
expression level are also likely to have implications on the uptake of glucose into the 
brain. 
In addition, there was also a drastic depreciation in the brain insulin levels that 
occurred as Aβ amounts increased in the APPsw/PS1∆E9 mouse brain. Insulin has 
been shown to regulate the uptake of glucose in the brain, especially in the cortical 
regions (Bingham et al. 2002). Therefore, major fluctuations in the levels of insulin 
might affect the total brain glucose content. Here, an inverse relationship between 
brain insulin levels and Aβ was found. In particular, as the Aβ42 levels increased, the 
levels of brain insulin decreased. To date, Aβ has not been shown to mediate the 
degradation of insulin. Therefore, it is likely that the low brain insulin levels might be 
related to the decrease in cerebral blood flow instead that has been previously 
documented in mice overexpressing APP that produce significant amounts of Aβ 
(Niwa et al. 2002). 
Depreciating levels of brain insulin are likely to cause a reduction in the 
intracellular insulin signaling since the binding of insulin to its receptors is crucial in 
triggering the autophosphorylation and subsequent activation of the insulin receptor 
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for glucose uptake. Coupled with a decline in the expression of GLUT-4 at the later 
timepoints of 12 and 15 months in the APPsw/PS1∆E9 mice, it is likely that the 
amount of GLUT-4 available for translocation to the plasma membrane after insulin 
activation and the subsequent uptake of glucose would be greatly reduced, 
contributing to a marked decline in brain glucose uptake. The situation is likely to 
worsen with a decrease in the cerebral blood flow caused by Aβ accumulation with 
time, which also means that less glucose would be supplied to the brain. Added 
together, these observations are likely to result in the overall low brain glucose content 
detected in APPsw/PS1∆E9 mice at 12 and 15 months of age. 
Interestingly, an upregulation of IGF-1R and IRS proteins was also observed 
in the APPsw/PS1∆E9 mice at the later timepoints. Further, an increase in IGF-1R 
expression has also been observed in AD brains (Moloney et al. 2010), which is in 
line with our current observations. Since IGF-1R can function as an insulin receptor 
while IRS serves to amplify insulin signaling, it is likely that the upregulation of these 
proteins probably serve as compensatory responses to the low brain insulin present. 
However, despite attempts to restore normal insulin signaling, there was still a 
reduced Akt activation that was detected with aging in the APPsw/PS1∆E9 mice. 
Thus it is possible that the low amount of brain insulin is a limiting factor in the 
initiation of insulin signaling in the transgenic mice, resulting in a gradual decline in 
Akt activation that occurred with aging and Aβ production in the mice. The finding of 
a decreased Akt activation also highlights how reduced insulin signaling, brought 
about by brain insulin deficiency and high Aβ, might contribute to increased tau 
phosphorylation, since Akt activation serves to inactivate GSK-3β that is responsible 
for the phosphorylation of tau, which forms the intracellular neurofibrillary tangles 
characteristic of AD. 
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An investigation of the expression of mitochondrial complex proteins also 
found a consistent downregulation of mitochondrial complex I protein in the 
APPsw/PS1∆E9 mice. This decrease in complex I expression was detected as early as 
3 months of age in the transgenic mice brain, suggesting that mitochondrial complex I 
is probably sensitive to small amounts of Aβ. A decline in the protein expression of 
complex I might translate to a decrement in complex I activity, thus affecting the 
overall functionality of the mitochondria. Previous studies characterizing the effect of 
Aβ on cultured cells have also found a reduction of mitochondrial complex I activity 
when cells were incubated with the peptide (Cardoso et al. 2001); which further 
implicates a role of Aβ in the modulation of mitochondrial function. This might also 
account for the decline in ATP formation that is commonly observed in the AD brain 
(Hoyer 1992). 
Taken together, my results suggest that Aβ exerts a differential effect on 
glucose metabolism that is dependent on the concentration of the peptide present. At 
low concentrations of Aβ, a decline in the CMRglc was observed, as evidenced by the 
high glucose and low pyruvate content. This might also account for why glucose 
hypometabolism, marked by low CMRglc is detected and more pronounced in the 
early stage of AD. At higher concentrations of Aβ, there was a pronounced defect in 
glucose uptake, likely caused by a deficiency in brain insulin and decreased 
expression of GLUT molecules, which probably overrode the effect caused by a drop 
in CMRglc, resulting in an overall decrease in brain glucose. The implications of these 
findings are that alterations in glucose metabolism likely occur alongside the 
deposition of Aβ in AD.                                                
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7. Conclusion and future perspectives 
In this thesis, different aspects of APP on the regulation of glucose metabolism 
in the brain were investigated. Specifically, the role of different APP isoforms and Aβ 
were examined, both of which have been related to the pathogenesis of AD.  
 
7.1 APP regulates glucose metabolism and the upregulation of APP751 in 
AD might be beneficial       
APP751 has long been associated with AD since studies have found an increase 
in the production of KPI-positive mRNA in AD brains (Tanaka et al. 1992) and an 
increase in the mRNA ratio of APP751 to APP695 in AD that correlated with plaque 
density in AD (Johnson et al. 1990). As such, it was widely believed that upregulation 
of the KPI positive APP751 isoform was associated with Aβ deposition and 
neurodegeneration in AD.    
My work using APP null neuronal cell lines transfected with the APP695sw and 
APP751sw isoforms have yielded surprising results. Firstly, both APP isoforms were 
found to produce differential amounts of Aβ in neuronal cells, with the APP751sw 
isoform generating significantly less Aβ than the APP695sw isoform. Applying the 
results to the context of AD, the direct implications are that increasing the expression 
of APP751 might serve to limit the amount of plaques formed through reducing the 
amount of Aβ produced.   
Secondly, the presence of both APP isoforms appears to modulate intracellular 
glucose content, resulting in an increase in intracellular glucose and consequently 
pyruvate levels. However, although APP695sw cells possessed a higher glucose and 
pyruvate content than APP751sw cells, this increase in intracellular glucose was 
associated with a marked elevation of mitochondrial activity that culminated in high 
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ROS production and increased caspase-3 activation, both of which are detrimental to 
cells. Further, the increased mitochondrial activity was likely caused by the increased 
expression of TCA and oxidative phosphorylation genes in APP695sw cells.   
This increased gene expression in APP695sw cells might be associated with an 
elevated production of the AICD in APP695sw cells, since previous studies have 
found an association between the amount of AICD and Aβ produced by neuronal cell 
lines that overexpress APP. As such, future work can be directed at deciphering the 
repertoire of metabolic genes possibly regulated by AICD to allow a deeper 
understanding of the role that each APP isoform plays in glucose metabolism. 
Additionally, a correlation between GLUT-3 expression and intracellular 
glucose content was also observed. Since the upregulation of GLUT-3 protein 
expression or activity might be responsible for the high glucose levels in APP695sw 
cells, further work involving RNA interference of GLUT-3 can also be done to 
investigate the plausible role of GLUT-3 in glucose uptake in these neuronal cells.    
 
7.2 APP751 prevents insulin resistance in neuronal cells: implications to 
AD 
Another area which was examined in this thesis was the role that each APP 
isoform might play in neuronal intracellular insulin signaling. It was observed that the 
expression of APP695sw resulted in the development of insulin resistance mainly by 
decreasing the expression of IRS molecules that are involved in the amplification of 
insulin signaling, thus resulting in a reduced activation of Akt. Conversely, APP751sw 
expression appears to restore insulin signaling and Akt activation in the neuronal cell 
line. 
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Although insulin signaling is known to regulate GLUT-4 translocation to the 
cell surface, no decrease in GLUT-4 surface expression for both APP transfected cells 
was observed despite a drop in IRS levels and Akt activation in APP695sw cells. 
Since GLUT-4 translocation also requires the activation of other proteins such as 
TC10 (Chiang et al, 2001), which is dependent on insulin receptor activation and not 
Akt activation by IRS, it is possible that changes in GLUT-4 translocation will only be 
detectable when insulin receptor activation is affected as well.  
As mentioned, it is possible that the reduced Akt activation in APP695sw cells 
might be associated with an increased FoxO activity. Therefore it is likely that the 
increased FoxO activity might result in an alteration of the expression profile of 
certain genes, thus accounting partially for the increase in TCA and oxidative 
phosphorylation gene expression observed.     
Finally, the reduced Akt activation in APP695sw cells leads to an increase in 
GSK3β activation, which has been linked to tau phosphorylation in AD. Since AD is 
commonly associated with the development of insulin resistance and 
hyperphosphorylation of tau in the brain, the expression of APP751, which maintains 
the levels of key insulin signaling molecules like IRS would be beneficial in reducing 
the extent of insulin resistance and tau phosphorylation.  
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Figure 7.1 Schematics of regulation of glucose metabolism by APP isoforms. 
 
(a)APP695sw expression results in the increased production of AICD and enhanced FoxO activity (due 
to the reduced insulin signaling). This might result in an increased expression of TCA and oxidative 
phosphorylation genes, thus giving rise to a higher mitochondrial activity. Cells with higher 
mitochondrial activity are likely to produce elevated amounts of reactive oxygen species (ROS) that 
might be associated with an increased tendency for them to undergo apoptosis. (b) APP751sw reverses 
the phenomenon observed in APP695sw, thus resulting in an overall lower mitochondrial activity, due 
to lower amounts of AICD and activated FoxO that cause less TCA and oxidative phosphorylation 
genes to be produced. This would result in decreased ROS generation and protect cells from being 
vulnerable to apoptosis. 
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7.3 Aβ regulates glucose metabolism differentially in a concentration 
dependent manner 
Lastly my studies of the APPsw/PS1∆E9 mice revealed that Aβ, when produced 
at high concentrations appears to affect glucose uptake by altering the expression of 
GLUT molecules and brain insulin content. A decline in the CMRglc at low 
concentrations of Aβ was also observed that probably persisted during aging. This 
suggests that defects in the CMRglc likely occur during the early stages of AD when 
Aβ is present in smaller amounts. As the amount of Aβ increases with the progression 
of the disease, defects in glucose uptake are likely to be more pronounced than a 
declining CMRglc thus resulting in an overall decline in glucose content instead of 
increased brain glucose concentrations. These reported findings could probably 
explain why some imaging studies have found correlations between Aβ and CMRglc, 
while others did not managed to, since there is the additional confounding factor of 
defective glucose uptake that might occur with higher amounts of Aβ. 
 
7.4 Concluding remarks      
Taken together, my findings support a role for APP in the regulation of energy 
homeostasis, in the context of glucose metabolism in various aspects. There is also 
convincing evidence that portrays the upregulation of APP751 as a favorable 
phenomenon in AD, contrary to popular belief. As such it might be necessary to 
include APP751 in future studies investigating other functional aspects of APP for a 
complete understanding of the role of APP in the brain and in AD.             
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